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ABBREVIATIONS 
 
AA   Arachidonic acid 
BRCA   Breast cancer gene 
CAM   Cell adhesion molecule 
CDK   Cyclin-dependent kinase 
CKI   Cyclin-dependent kinase inhibitor 
COX   Cyclooxygenases 
CYP   Cytochrome P450 
Di-GA   Di-galloyl-resveratrol 
DNA   Deoxyribonucleic acid 
ECM   Extracellular matrix 
EGFR   Epidermal growth factor receptor 
EMT   Epithelial-mesenchymal transition 
FGF   Fibroblast growth factor 
GA   Gallic acid 
GAPDH  Glyceraldehydes-3-phosphate dehydrogenase 
HER2   Human epidermal growth factor type 2 
HETE   Hydroxyeicosatetraenoic acid 
HPETE  Hydroperoxyeicosatetraenoic acid 
HTLV-1  Human T-cell leukaemia virus 1 
HUVECs  Human umbilical vein endothelial cell 
IC50   Concentration which inhibits by 50 %  
ICAM   Intracellular adhesion molecule 1 
IL-1   Interleukin 1 
INK4   Inhibitors of Cdk4 
LEC   Lymphendothelial cell 
LOX   Lipoxygenase 
LPS   Lipopolysaccharide 
MMP   Matrixmetalloproteinase 
MT-MMP  Membrane-type matrixmetalloproteinase 
NDGA  Nordihydroguaiaretic acid 
NEAA   Non essential amino acid 
NF-ĸB   Nuclear factor kappa B 
  
PDGF   Platelet-derived growth factor 
PECAM  Platelet-endothelial cell adhesion molecule 1 
PG   Prostaglandins 
PIC   Piceatannol 
RB   Retinoblastoma tumor suppressor gene 
RNA   Ribonucleic acid 
RR   Ribonucleotide reductase 
RHD   Rel homology domain 
RV   Resveratrol 
TNF   Tumor necrosis factor 
VE-cadherin  Vascular endothelial cadherin 
VEGF   Vascular endothelial growth factor
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Zusammenfassung 
 
Wie in vorausgehenden Studien beschrieben wurde, ist Brustkrebsmetastasierung 
abhängig von der Aktivität von Lipoxigenasen, welche 12(S)-HETE generieren. 
12(S)-HETE wird von MCF-7 Tumorzellspheroiden produziert und freigesetzt und 
induziert dabei eine Spaltformation in Lymphendothelzell Monolayers. Ein 3D Ko-
Kultur System imitiert das Eindringen von Brustkrebszellen in das lymphatische 
Gefäßsystem und fasst den Mechanismus der Metastasierung zusammen.  
In dieser Arbeit untersuchten wir einen spezifischen 12/15 Lipoxigenase Hemmer, 
Baicalein, und das strukturell gleich gebaute Wogonin um Spaltformationen zu 
hemmen.  
Neben 12(S)-HETE haben wir auch NF-ĸB als wichtigen Mitwirkenden in der 
Spalformation identifiziert. Demzufolge testeten wir Verbindungen wie Di-galloyl-
resveratrol, Resveratrol und Gallussäure sowie deren Derivate mit vermeintlicher 
Hemmwirkung von NF-ĸB in diesem 3D Metastasierungs Ko-Kultur Model. 
Unter den synthetischen Drogen untersuchten wir auch natürlich vorkommende 
Substanzen, wie Hyperforin, welches ein Hauptbestandteil von Hypericum 
perforatum ist. 
Die Aktivierung von NF-ĸB ist verbunden mit Zellproliferation, Zellüberleben, 
Zelleindringen und Angiogenese. Dies macht NF-ĸB zu einem interessanten Ziel in 
der Krebsbekämpfung.  
Wir untersuchten einen irreversiblen Hemmer von NF-ĸB – Bay11-7082. 
Aufgrund der Hemmwirkung von Bay11-7082 in der Spaltformation untersuchten 
wir die NF-ĸB vermittelte Lymphendothelzellbewegung, welche die ZEB-1 
abhängige Expression von VE-cadherin und die Anhaftung von Tumorzellen an 
Endothelzellen miteinbezogen hat. Die Anhaftung von Tumorzellen an das 
Endothelium stellt den ersten Schritt der Metastasierung dar. Wir beschrieben die 
mögliche Rolle von drei NF-ĸB regulierten Ligand – Rezeptor Pärchen in 
Tumorzelladhesion an das Endothelium, ICAM-1/αLβ2, CD31/ αVβ3 und E-selectin/ 
CD44. 
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Summary 
 
Ductual breast cancer metastasis depends on the expression and activity of 
lipoxygenases, which generate 12(S)-HETE. 12(S)-HETE is produced and 
released by MCF-7 tumor cell spheroids and induces gaps in a LEC monolayer. A 
3D co-culture system mimics the invading of breast cancer cells to the lymphatic 
vasculature and recapitulates the mechanisms of metastasis. In this work I 
investigated a specific inhibitor of 12/15-Lipoxygenase, Baicalein, and the 
structurally highly related Wogonin on inhibition of gap formation.  
Besides 12(S)-HETE, we could identify also NF-ĸB as a major player in MCF-
7/LEC gap formation. Therefore, we tested compounds, such as Di-galloyl-
resveratrol, Resveratrol and Gallic acid and their derivatives, with putative NF-ĸB 
inhibitory properties in this 3D metastasis co-culture model.  
Among the synthetic drugs we also studied natural compounds, such as 
Hyperforin, a main constituent of Hypericum perforatum.  
NF-ĸB activation is associated with tumor cell proliferation, survival, invasion and 
angiogenesis. This makes NF-ĸB an interesting target for the treatment of cancer. 
We investigated an irreversibly inhibitor of NF-ĸB – Bay11-7082.  
Due to the Bay11-7082 inhibitory effects on gap formation we studied the NF-ĸB 
mediated LEC motility, including ZEB1 dependent expression of VE-cadherin and 
the adhesion of tumor cells to the endothelial cells which represents the first 
important event in the process of metastasis. We described the possible role of 
three bonafide NF-ĸB-regulated ligand – receptor pairs in tumor cell adhesion to 
the endothelium, ICAM-1/αLβ2, CD31/ αVβ3 and E-selectin/ CD44.  
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1. Introduction 
 
1.1. Hallmarks of Cancer 
Hanahan and Weinberg described in the year 2000 six essential alterations in cell 
physiology that identify malignant growth.  
 
 
 
 
 
 
 
 
 
 
 
Figure I: The six hallmarks of cancer (Hanahan and 
Weinberg 2000) 
 
 
1.1.1 Self-sufficiency in growth signals 
Each normal cell needs a mitogenic growth signal (GS) before they can move from 
the G0/G1 state of the cell cycle into a proliferative state.  
These signals are for example diffusible growth factors, extracellular matrix 
components and cell-to-cell adhesion molecules. They are transmitted into the cell 
by transmembrane receptors that bind these signals. Many of the oncogenes 
imitate the activation of such growth signals and the conclusion is that tumor cells 
can start the proliferation machine on their own (Hanahan and Weinberg 2000). 
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1.1.2 Insensitivity to growth-inhibitory (antigrowth) signals 
In a normal tissue it is necessary to maintain cellular quiescence and tissue 
homeostasis. Growth-inhibitory signals operate to remain this and are received by 
transmembrane cell surface receptors coupled to intracellular signaling circuits. 
They can stop proliferation in two different mechanisms.  
Some signals can force the cell to leave the active proliferate cycle and join the G0 
raste state. They may reemerge in future when extracellular signals permit. 
Other signals may induce the cells to cancel their proliferative potential by entering 
postmitotic states, which usually associated with acquisition of specific 
differentiation-associated traits (Hanahan and Weinberg 2000). 
Loss of an antigrowth signaling circuitry leads to the development of cancer. 
 
1.1.3 Evasion of programmed cell death (apoptosis) 
Apoptosis represents a major source of cell attrition. To achieve homeostasis the 
rate of cell proliferation and cell attrition should be in balance. An insufficient 
amount of apoptosis results in uncontrolled cell proliferation, and further cancer. 
Two major components are important for the apoptotic machinery. The sensors are 
necessary to control the extracellular and intracellular environment for conditions of 
normality or abnormality that influence whether a cell should live or die (Hanahan 
and Weinberg 2000).  
The effectors of apoptotic death are regulated from intracellular sensors. They 
activate the death pathway in response to detection abnormalities, including DNA 
damage, signaling imbalance provoked by oncogene action, survival factor 
insufficiency or hypoxia (Evan and Littlewood 1998). Most and perhaps all types of 
cancer cells are able to evading apoptosis. 
 
1.1.4 Limitless replicative potential 
Self-sufficiency in growth signals, insensitivity to antigrowth signals and evasion of 
programmed cell death lead to an uncoupling of a cells growth program from 
signals in its environment. Many types of cells carry an intrinsic, cell-autonomous 
program that limits their multiplication. They stop growing after a certain number of 
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doublings. Tumor cells appear to be immortalized because they have a limitless 
replicative potential, which is essential for the development of their malignant 
growth (Hanahan and Weinberg 2000).  
 
1.1.5 Sustained angiogenesis 
Oxygen and other nutrients are supplied by the vasculature and they are important 
for cell function and survival. Thereby cells are obligating to reside within 100 µm of 
a capillary blood vessel. Because of this dependence on nearby capillaries, 
proliferating cells within a tissue would have an intrinsic ability to encourage blood 
vessel growth (Hanahan and Weinberg 2000). 
The initiating signals for angiogenesis are the vascular endothelial growth factor 
(VEGFC) and acidic or basic fibroblast growth factors (FGF1/2). These factors bind 
to transmembrane tyrosine kinase receptors displayed by endothelial cells (Fedi et 
al. 1997, Veikkola and Alitalo 1999). In many tumors the expression of VEGF 
and/or FGF is increased.  
 
1.1.6 Tissue invasion and metastasis 
The final capability during tumorgenesis is tissue invasion and metastasis. These 
are complex processes, and their genetic and biochemical determinants are not 
completely understood. 
In the development of most types of human cancer, cells remove from the primary 
tumor masses and move out, invade adjacent tissues and thence travel to distant 
sites to colonize new terrain in the body. This process is called metastases 
(Hanahan and Weinberg 2000). 
Metastases, the distant settlements of tumor cells are the cause of 90% of human 
cancer deaths (Sporn 1996). 
The activation of extracellular proteases and the binding specificities of cadherins, 
cell adhesion molecules (CAMs) and integrins are the most important steps for the 
acquisition of invasiveness and metastatic ability (Hanahan and Weinberg 2000). 
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1.2. Oncogenes and tumor suppressor genes 
 
Most types of cancer occurs form mutations in genes that are involved in cell 
growth, differentiation and death. Oncogenes and tumor suppressor genes are two 
major classes of mutated genes that play a pivotal role in carcinogenesis. 
An oncogene is a mutated gene and the produced protein of this oncogene has 
increased activity. Mutations in only one allele are sufficient for an effect. 
In tumor suppressor genes the mutation caused a loss of function. Both alleles 
must be mutated (Pecorino 2008). In this chapter I want to give a short overview of 
the oncogenes and the most important tumor suppressor genes p53 and RB. 
 
1.2.1 Oncogenes 
The produced proteins of an oncogene control cell proliferation, apoptosis or both. 
Oncogenes can be activated by chromosomal rearrangements, mutations and 
gene amplification and can thereby cause a rearrangement in the oncogene 
structure, an increase in its expression or a deregulation of its expression (Bishop 
1991). 
The products of oncogenes include:  
 growth factors: the product of the proto-oncogene c-sis is platelet-derived 
growth factor (PDGF). It is normally secreted by platelets and stimulates 
epithelial cells around the wound to proliferate and repair the damage. The 
oncogenic form is located in the cytoplasmic and leading to unregulated 
growth. 
 growth factor receptors: the product of the proto-oncogene c-erbB is 
epidermal growth factor receptor (EGFR). This receptor is mutated in many 
tumors and triggers cell division in the absence of EGF.  
 signal transducers: e.g. mutation in the ras gene leading to constitutive 
activation of RAS protein because of a loss of GTPase activity. Signals were 
continuously transducer and this induces limitless cell growth. 
 transcription factors: e.g. AP-1 is an important regulator of cell growth, cell 
differentiation and cell death (Pecorino 2008).  
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 apoptosis regulators: BCL2 is up-regulated in many cancers and inhibit 
apoptosis (Adams and Cory 2007) 
 
1.2.2 Tumor suppressor genes 
RB (retinoblastoma tumor suppressor gene) 
The retinoblastoma tumor suppressor gene was first detected in 1971 by Knudson. 
The major role of RB is to regulate the cell cycle by inhibiting the G1 to S-phase 
transition. Thereby it interacts with transcription factors such as E2Fs. These are 
important for regulating several genes which are essential for DNA metabolism and 
replication (Nevins 2001, Trimarchi and Lees 2002). The bound of RB to E2F 
resulted in inhibition of transcription and is regulated by cyclin-dependent kinases. 
Phosphorylation of RB by CDKs leads to the inactivation of RB and as a 
consequence to limitless cell proliferation. In the majority of cancers the RB protein 
is mutated or inactivated (Van den Heuvel and Dyson 2008). 
 
p53 (Protein 53) 
The tumor suppressor gene p53 was first detected in 1979 (Sherr 2004). It is a 
transcription factor and has a pivotal role in cellular response to stress signals, 
including DNA damage, oncogenic activation, hypoxia or irradiation (Vogelstein et 
al. 2000). Therefore the activation of p53 leads to cell cycle arrest or DNA repair, 
apoptosis or senescence. In normal tissues the p53 levels are very low. In tumor 
cells the p53 gene was either deleted or mutated (Baker et al. 1990). 
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1.3. Cell cycle 
Disorders in the regulation of the cell cycle are important events in the 
development of cancer. Complex networks of regulatory factors decide whether 
cells proliferate or die. The DNA in every mammalian cell is under constant attack 
by agents, including solar radiation, polycyclic aromatic hydrocarbons and cigarette 
smoke etc. Cellular DNA-damage can result in the development of cancer (Meeran 
and Katiyar 2008). 
 
1.3.1 Cell cycle progression 
The cell cycle includes the duplication of cell contents and subsequent cell division. 
It consists of four distinct phases:  
Gap1 phase (G1): cells preparing for DNA synthesis  
S-phase (S): DNA synthesis and replication  
Gap2 phase (G2): responsible for protein synthesis 
M-phase (M): chromosome separation and cell division  
 
The Gap0 phase is a resting state, in which cells do not grow and proliferate. 
Among these phases there are several checkpoints, which protect cells from 
cellular damage and stress signals and maintain the fidelity of DNA replication, 
repair and division (Pietenpol and Stewart 2002). One checkpoint is between G1 
and S-phase, the next checkpoint is between G2 and M-phase and the last one is 
the spindle checkpoint in mitosis phase. 
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Figure II: Cell cycle control of eukaryotic 
cells. Key regulators are cyclin-dependent 
kinase complexes (CDKs) which ensure 
that all phases of the cell cycle are 
executed in the correct order. CDKs are 
activated when they become bound to 
regulatory proteins (cyclins). CDK activity 
is suppressed through interactions with 
inhibitory proteins (INK CDK inhibitors) 
(Dehay and Kennedy 2007). 
 
 
 
 
 
1.3.2 Control of the cell cycle 
Cellular responses to DNA damage result in the arrest of the cell cycle in order to 
provide time for DNA repair. Therefore the transition from one cell cycle phase to 
another is regulated by the activities of protein kinase complexes. Key regulators 
are cyclin-dependent kinase complexes (CDKs), which are activated when they 
become bound to regulatory proteins (cyclins). During cell cycle CDK4, CDK6, 
CDK2 (in G1 phase) CDK2 (in the S phase) and CDK1 (in G2 and M phase) are 
active. Their regulatory proteins, cyclins, can be divided in cyclin A, B, D1-D3 and 
E.  
There are also cell cycle inhibitory proteins, called CDK inhibitors (CKI). They can 
bind to CDK alone or to the CDK-cyclin complex and regulate their activity. The 
CKI can be differentiating in two different families, the CIP and the INK4 family. 
The most important member of the CIP family is p21, which is under transcriptional 
control of the p53 tumor suppressor gene (Vermeulen et al. 2003). 
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1.4. Cell death  
Cell death is a fundamental process in development, homeostasis and immune 
regulation. Dysregulation of cell death is often associated with numerous 
pathologies (Duprez et al. 2009). There are three types of cell death: 
 
 The programmed cell death – apoptosis 
 Necrosis 
 Autophagic cell death  
 
 
 
 
Figure III: The apoptotic and necrotic cell death process (Goodlett and Horn 2001). 
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1.4.1 Apoptosis 
In 1972, the term apoptosis was described for the first time. It is a programmed 
suicide mechanism that results in the controlled breakdown of the cell into 
apoptotic bodies. These apoptotic bodies are recognized and engulfed by 
surrounding cells and phagocytes. Apoptosis is characterized by cell shrinkage, 
membrane blebbing and chromatin condensation (Duprez et al. 2009). 
 
1.4.2 Necrosis 
Necrosis is associated with cytoplasmic and organelle swelling, followed by the 
loss of cell membrane integrity and release of the cellular contents into the 
surrounding extracellular space (Duprez et al. 2009). 
 
1.4.3 Autophagic cell death 
Autophagy allows eukaryotes to degrade and recycle cellular components. 
Proteins and organelles are excreted in specialized double-membrane vesicles, 
which are typical of autophagic cells. Many studies have revealed diverse functions 
of autophagy in maintenance of intracellular homeostasis, differentiation, 
development, longevity and immune defense. Massive autophagic activity could 
result in cellular demise (Maiuri et al. 2007, Duprez et al. 2009). 
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1.5. Breast cancer 
Breast cancer is the most common cause of cancer death among women 
worldwide. Approximately 519.000 women died in 2004 due to breast cancer. 
Breast cancer is a disease of the developed world. 69 % of all breast cancer 
deaths occur in developing countries where the majority of cases are diagnose in 
late stages (WHO Global Burden of Disease 2004).  
 
1.5.1 Risk factors of breast cancer 
 The incidence of breast cancer increases rapidly with age.  
 Breast cancer in one breast increases the risk of cancer in the other breast. 
 The risk of breast cancer increases two fold if the mother, father, sister or 
daughter had breast cancer. 
 Mutations in the gene BRCA1 or BRCA2 increase the risk of breast cancer 
 The risk of breast cancer increased in women who had radiation therapy to 
the chest before age 30. 
 The younger a woman is when she begins menstruating, the higher her risk 
of breast cancer. 
 With increasing age at first full term pregnancy the risk of breast cancer is 
increased. Nulliparous women have an increased risk of breast cancer. 
 Women who went through menopause at a late age and women who use 
hormonal therapy for the menopause are at higher risk of breast cancer. 
 The risk of breast cancer is higher in women who are overweight or obese 
after menopause. 
 Women who are physically inactive throughout life have a higher risk of 
breast cancer. 
 The more alcohol a woman drinks, the greater her risk of breast cancer 
(http://www.cancer.gov/cancertopics/wyntk/breast/page4 last access 10 
January 2010). 
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1.5.2 Treatment of cancer 
There are different types of treatment for patients with breast cancer. Surgical 
resection is mostly the first step in treatment of breast cancer. After surgery 
patients get radiation therapy, chemotherapy or target-tailored therapy (e.g. 
Herceptin) to kill any cancer cells that are left. Thereby the prognosis and 
treatment options depend on the stage of cancer, the type of breast cancer and 
estrogen-receptor and progesterone-receptor levels in the tumor tissue. Other 
treatment options depend on how fast the tumor is growing, the age of the women, 
general health and menopausal status and whether the cells have high levels of 
human epidermal growth factor type 2 receptors (HER2/neu) 
(http://preview.cancer.gov/cancertopics/wyntk/breast/page8#f last access 10 
January 2010). 
60% of all drugs used in western medicine are derived from natural compounds 
(Cragg et al. 2006). Pharmaceutical companies collect marine organisms, bacteria, 
fungi and plants at random to test them in robot-screenings regarding their anti-
cancer-, anti-inflammatory-, anti-bacterial- etc. activities. In Turkey a rich botanical 
biodiversity is found.  
The genus Scutellaria has acquired considerable interest concerning anticancer 
activities (Yin et al. 2004). Scutellaria baicalensis is known as Huang-qin and is a 
most commonly used plant in Traditional Chinese Medicine (TCM). The root of 
Scutellaria baicalensis is use to treat various inflammatory conditions (Ma et al. 
2005). Lee et al. 2008 have studied baicalein in detail and showed anticancer 
effects in human hepatoma cell lines (Himeji et al. 2007). Baicalein is reported to 
be a specific inhibitor of 12/15 lipoxygenases and is a major constituent of the plant 
Scutellaria baicalensis (Chen et al. 1999, Hsieh et al. 2007) and Scutellaria 
orientalis (Özmen et al 2009). The genus Hypericum is also used in different folk 
medicines worldwide and is tested against cancer cell growth. Hyperforin, a main 
constituent of Hypericum perforatum and Hypericum adenotrichum was shown to 
inhibit tumor growth, induce apoptosis of tumor cells and reduce tumor 
vascularisation (Schempp et al. 2005). 
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In my work I examine both these constituents of natural compounds and also 
synthetic compounds to study the treatment of cancer. 
  
1.6. Metastasis mechanism 
Metastasis is the cause of more than 90 % of all cancer deaths (Sporn 1996). It is 
the spread of tumor cells to distant sites, usually via the bloodstream, lymphatic 
system or through body spaces (Willis 1973). 
Geiger and Peeper (2009) described the classical view on the metastatic cascade:  
 Creation of a „premetastatic niche“ 
 EMT (epithelial-mesenchymal transition) and degradation of the basement 
membrane  
 Dissociation of tumor cells from the bulk tumor 
 Invasion of tumor cells into surrounding tissue 
 Intravasation into blood and lymph vessels 
 Transport through vessels 
 Extravasation 
 Establishment at a secondary anatomical site 
 Outgrowth of secondary tumors 
 
1.6.1 Epithelial-mesenchymal transition (EMT)  
EMT is a biologic process that allows a polarized epithelial cell to undergo multiple 
biochemical changes to assume a mesenchymal cell phenotype. Carcinoma cells 
which are seen at the invasive front of primary tumors can get a mesenchymal 
phenotype. Thereby, the expression of proteins such as E-cadherin and γ-catenin 
can be lost and mesenchymal markers such as vimentin, S100A4, fibronectin, 
MMP-2 and MMP-9 can be acquired (Min et al. 2008, Zeisberg and Neilson 2009). 
This result in enhanced migratory capacity, invasiveness, elevated resistance to 
apoptosis and greatly increased production of ECM components (Kalluri and 
Neilson 2003). 
Distinct molecular processes are necessary to initiate an EMT and enable it to 
reach completion. 
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EMT is classified in three different biological settings that carry various functional 
consequences. Type 1 EMTs are associated with implantation, embryogenesis and 
organ development. Type 2 EMTs are associated with wound healing, tissue 
regeneration and organ fibrosis.  
The third type of EMT is the most important one for my diploma thesis. It is 
associated with cancer progression and metastasis (Kalluri and Weinberg 2009). 
 
 
Figure IV: Type 3 of EMT. Epithelial cells losing their polarity and detaching from the basement 
membrane. The composition of the basement membrane is changing. Then, epithelial to 
mesenchymal transition permit cancer cells to enter the circulation and exit the blood stream. There 
the cancer cells may form micro- and macro-metastases (Kalluri and Weinberg 2009). 
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1.7. Arachidonic acid metabolism 
The arachidonic acid metabolism leads to the generation of various biologically 
active eicosanoids. They have been shown to regulate numerous aspects of tumor 
development. 
Three types of enzymes can metabolize arachidonic acid (AA). These enzymes are 
cyclooxygenases (COX), epoxygenases (cytochrome P450) and lipoxygenases 
(LOX). They insert oxygen at different positions in AA to generate eicosanoids 
(Moreno 2009, Pidgeon et al. 2007).  
 
1.7.1 Lipoxygenases 
5-LOX, leukocyte and platelet-type 12-LOX and reticulocyte-type 15-LOX-1 are the 
most studied LOX enzymes. These four LOXs metabolize arachidonic acid (AA) to 
the hydroperoxyeicosatetraenoic acids (HPETEs) which are subsequently 
converted to hydroxyeicosatetraenoic acid (HETE) (Moreno 2009, Pidgeon et al. 
2007). 
 
Type Synthesize  
5-LOX 5(S)-HETE Epithelial cancers (breast 
cancer, prostate, lung etc) 
Platelet-type 12-LOX 12(S)-HPETE 
12(S)-HETE 
Smooth muscle cells, 
keratinocytes, endothelial 
cells and tumor cells Leukocyte type 12-LOX 15(S)-HETE 
12(S)-HETE 
15-LOX-1 13-(S)-HODE 
15-(S)-HETE 
Reticulocytes, eosinophils 
and airway epithelial cells, 
macrophages, 
atheriosclerotic lesions 
15-LOX-2 15-HETE  
(Moreno 2009, Pidgeon et al. 2007) 
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12(S)-HETE 
 
 
Figure V: Chemical structure of 12(S)-hydroxyeicosatetraenoic acid 
 
12(S)-HETE is the 12-lipoxygenase metabolite of arachidonic acid and induces a 
reversible retraction of cultured endothelial cells. 12(S)-HETE have an important 
role in facilitating cancer metastasis (Chen et al. 1994, Honn et al. 1994). 
12(S)-HETE is produced and released by MCF7 tumor cell spheroids and induced 
gaps in LEC monolayer (Kerjaschki et al. 2010). In our study we used 1 µM 12(S)-
HETE to stimulates LECs. This mimics the 3D co-culture system of MCF-7 
spheroids and LECs and further the invading of breast cancer cells to the lymphatic 
vasculature (Uchide et al. 2007, Kerjaschki et al. 2010, Kramer and Nicolson 
1979). 
Numerous of plant phenols, such as Baicalein, Resveratrol and 
Nordihydroguaiaretic acid (NDGA) are known for their chemo-preventive and LOX-
inhibitory activity in many tumor models (Bednar et al. 2006). Wang et al. (2010) 
showed the strong anti-proliferative effect of Baicalein on MCF-7 human breast 
cancer cells. 
Baicalein (figure VI, left) is a major constituent of the plant Scutellaria baicalensis 
(Chen et al. 1999, Hsieh et al. 2007) and Scutellaria orientalis (Özmen et al. 2009). 
It is reported to be a specific inhibitor of 12/15-LOX (Chen et al. 1999, Hsieh et al. 
2007) and the root of Scutellaria baicalensis is use to treat various inflammatory 
conditions (Ma et al. 2005). Ductual breast cancer metastasis was shown to 
depend on the expression and activity of lipoxygenases in particular 12-LOX and to 
a minor extent 15-LOX. Hence, we assumed that Baicalein, the specific inhibitor of 
12/15-LOX, have a strong inhibitory effect on gap formation.  
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In fact, figure VI (right) shows an inhibition of gap formation with a maximum 
inhibition of about 60 %.  
 
 
O
OOH
OH
OH
 
 
 
Figure VI: Chemical structure of Baicalein (left) and gap formation assay (right). LECs were seeded 
in 24 well plates and allowed to grow for 2 days until confluence. Then, LECs were stained with 
cytotracker green (1:5000 dilution) for 1 hour at 37°C. MCF-7 mock cells were transferred to MEM 
medium with hygromycin B containing methylcellulose. 150 µl of this cell suspension were 
transferred to each well of a 96 well plate to allow spheroid formation within the following two days. 
Then, MCF-7 mock spheroids, which were treated with different concentrations (solvent, 100 µM) of 
Baicalein for 30 min at 37°C, were carefully transferred to the wells of a 24 well plate containing 
LECs. These 3D MCF-7 spheroids/LECs monolayer co-cultures were incubated for 4 h at 37°C. The 
size of the gaps, which were formed in the LEC monolayers were measured using a Zeiss Axiovert 
microscope. For each condition, the gap area under at least 12 spheroids was measured. Error bars 
indicate SEM, asterisks significant gap formation inhibition compared to control (p<0.05)  
 
 
1.7.2 Cyclooxygenases 
There are two isoforms of cyclooxygenases (COX). COX-1 is expressed in most 
tissues and appears to generate prostaglandins (PG). Thus control platelet 
aggregation, regulation of renal blood flow and maintenance of the gastric mucosa. 
COX-2 increased rates of PG formation during tissue injury and repair 
(Fürstenberger et al. 2006). It is shown as a promising target for chemoprevention 
and treatment of several cancers (Fürstenberger et al. 2006, Krysan et al. 2006). 
The cyclooxygenases pathway metabolizes arachidonic acid to the unstable cyclic 
endoperoxides PGG2 and PGH2. In the next step they are converted to 
prostaglandins and thromboxanes by tissue specific synthases (Pidgeon et al. 
2007). 
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Membrane Phospholipids 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure VII: Lipoxygenase- and cyclooxygenase-catalyzed arachidonic acid metabolism. 
 
1.7.3 Epoxygenases (Cytochrome P450) 
Cytochrom P450 (CYP) proteins also metabolize arachidonic acid to produce 9-, 
11-, 16-, 17-, 18-, 19- and 20-HETEs. CYP are primarily expressed in the liver but 
they are also detected in the heart, vasculature, gastrointestinal tract, kidney, lung, 
in vascular smooth muscle cells and endothelium (Scarborough et al. 1999, Lin et 
al. 1996). 
Phosphatidylcholine Phosphatidylinositol 
5-HETE  
LTB4, cysteinyl LTs 
Phospholipase A2 Phospholipase C 
Cyclooxygenase 1/2 Lipoxygenase 5/8/12/15 
Arachidonic 
Acid 
PGG2 
PGH2 
HPETEs 12-HETE 
15-HETE 
Prostaglandins: 
PGD2, PGE2, 
PGF2α, PGI2 
Thromboxane: TXA2 Leukotriene A4 
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1.8. Matrixmetalloproteases 
Matrixmetalloproteinases (MMPs) have a crucial role in late stages of tumor 
progression. Tumor cell migration, invasion and metastasis are controlled by 
MMPs through ECM (extracellular matrix) degradation (Chabottaux and Noel 
2007). MMPs are multidomain proteins which can degrade virtually all ECM 
components and activate (or inactivate) and release a number of modulators of cell 
functions (Cauwe et al. 2007, Overall and Dean 2006, Egeblad and Werb 2002, 
Greenlee et al. 2007). Most of the MMPs are secreted as soluble enzymes but 
there are also membrane-type MMPs (MT-MMPs). They are associated with the 
cell membrane (Zucker et al. 2003). In vitro studies showed the effect of MMPs in 
tumor growth, angiogenesis and metastasis (Overall and Dean 2006, Noel et al. 
2007). MMPs are overexpressed in human cancer tissues (Egeblad and Werb 
2002). MMP-1, -2, -9, -11 and MT1-MMP are the most common in breast cancer 
tissues (Chabottaux and Noel 2007). 
 
Figure VIII: Sources of MMPs and implication in tumor progression (Chabottaux and Noel 2007). 
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1.9. NF-ĸB  
NF-ĸB is a transcription factor and plays a major role in inflammation, cell survival, 
transformation and cancer. NF-ĸB seems important in regulating the transcription 
of cytokines, adhesion molecules and other mediators (Sun and Andersson 2002). 
Five NF-ĸB members in mammals are identified: RelA (p65), RelB, c-Rel, NF-ĸB1 
(p50 and p105), and NF-ĸB2 (p52 and p100) (Ghosh and Karin 2002). These NF-
ĸB/Rel proteins can exist as homo- or heterodimers and share a highly conserved 
300 amino acid long N-terminal Rel homology domain (RHD). It is responsible for 
DNA binding, dimerization and association with the I-ĸB inhibitory proteins (Gosh et 
al. 1998). In the cytoplasm NF-ĸB exist in an inactive form that is bound to I-ĸB. 
The most important ones of these inhibitory proteins are I-ĸBα, I-ĸBβ and I-ĸBε. 
These I-ĸB family members share ankyrin-like repeats, which are protein-protein 
interaction domains that interact with NF-ĸB via the RHD (Ghosh et al 1998). 
 
1.9.1 NF-ĸB activation and inhibition 
In cells NF-ĸB can be activated by a wide variety of stimuli associated with stress 
or injury. Inducers of NF-ĸB are cytokines such as IL-1β and TNF-α, bacterial and 
viral products such as LPS, sphingomyelinase and the double-stranded RNA. 
Other inducers of NF-ĸB are the Tax protein from human T-cell leukaemia virus 1 
(HTLV-1), proapoptotic and necrotic stimuli such as oxygen free radicals, and 
ultraviolet light and γ-irradiation (Tran et al. 1997). NF-ĸB is associated with the 
signal-induced proteolytic degradation of I-ĸB in the cytoplasm. Proinflammatory 
cytokines such as IL-1β and TNF-α initiate a signalling cascade leading to 
activation of two I-ĸB kinases (IKK), IKKα and IKKβ, which phorsphorylate I-ĸB at 
specific amino-terminal serine residues (Zandi et al. 1997). Phosphorylated I-ĸB is 
then ubiquitinated and this phosphorylated and ubiquitinated I-ĸB, which is still 
associated with NF-ĸB in the cytoplasm, is selectively degraded by the 26S 
proteasome. This process was associated with the translocation of NF-ĸB to the 
nucleus. There it binds its target genes to initiate transcription (Sun and Andersson 
2002). 
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NF-ĸB protein activity is regulated by two major pathways. NF-ĸB proteins can form 
homo-and heterodimers. RelA (p65), RelB, c-Rel, NF-ĸB1 (p50 and p105), and NF-
ĸB2 (p52 and p100) are the five NF-ĸB members which were identified (Ghosh and 
Karin 2002). The classical pathway leading to activation of p50/RelA or p50/c-Rel 
and the alternative pathway leading to activation of p52/RelB or p50/RelB (Min et 
al. 2008, Cao and Karin 2003). 
 
Classical pathway    Alternative pathway 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure IX: Two major pathways of NF-ĸB activation. Classical pathway: Stimuli such as TNFα and 
IL-1 activate the IKK complex, which phosphorylates the I-ĸB protein. This process triggers the 
upiquitin-dependent degradation of I-ĸB by the 26S proteasome and results in nuclear translocation 
and of NF-ĸB1 (p105) which is processed to p50 and bound to RelA (p65) and I-ĸB in the 
cytoplasm. Alternative pathway: Stimuli such as LTβ (lymphotoxin β receptor) and BAFF lead to 
activation of NF-ĸB inducing kinase (NIK). NIK induces IKKα which activates the processing of 
p100/RelB into NF-ĸB2 p52/RelB via the proteasome (Cao and Karin 2003, Brown et al. 2008).  
TNFα, IL-1 LTβ, BAFF 
IKKγ 
IKKα IKKβ 
RelA 
p50 
 
I-ĸBα 
RelA p50 p52 RelB 
RelB 
NF-ĸB2 
P 
P 
NIK 
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1.9.2 NF-ĸB and inflammatory disease and cancer 
Nuclear factor kappa B plays a crucial role in inflammatory diseases such as 
rheumatoid arthritis and asthma. The production of IL β, TNF-α and Interleukin 6 is 
increased in these patients. 
The activation of NF-ĸB increases the expression of many genes involved in 
immune and inflammatory responses (Epstein et al. 1997). 
In all chronic inflammatory diseases adhesion molecules hire inflammatory cells 
such as neutrophils, eosinophils and T-lymphocytes from the circulation to the site 
of inflammation (Albelda et al. 1994). NF-ĸB regulates the expression of such 
genes that encode adhesion molecules. An important aspect of NF-ĸB in these 
diseases is the fact that it is activated by inflammatory cytokines and it induces the 
expression of inflammatory cytokines (Epstein et al. 1997). 
Numerous studies report that NF-ĸB could also be important in breast 
carcinogenesis (Cogswell et al. 2000, Nakshatri et al. 1996, Sovak et al. 1997). 
Thereby NF-ĸB activation has been linked to tumor progression via stimulation of 
cell proliferation, prosurvival, angiogenesis pathways and metastasis (Haffner et al. 
2006).  
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2. Material and Methods 
2.1. Material 
2.1.1 Chemicals 
Digalloylresveratrol, Gallic acid, Amidox, Didox, Trimidox, Resveratrol, M5 and M8 
were from Thomas Szekeres. Piceatanol was purchased from Sigma (MO, USA). 
Wogonin Cat# 681670 was purchased from Calbiochem (Darmstadt, Germany). 
Baicalein (El-106) and Bay11-7082 Cat# EI-278 were from Biomol (Hamburg, 
Germany). Hyperforin was purchased from Sigma (MO, USA). 12(S)-HETE Cat# 
34570 was purchased from Cayman Chemical (MI, USA). 
Monoclonal mouse anti-CD31 (JC70A) Cat# M0823 was purchased from DAKO 
(Glostrup, Denmark). Rabbit polyclonal anti-ZEB1 (H-102) sc-25388 and mouse 
monoclonal anti-αV Integrin (P2W7) sc-9969, mouse monoclonal anti-β2 Integrin 
(CTB104) sc-8420 and mouse monoclonal anti-αL Integrin (CRIS-3) sc-59741 were 
from Santa Cruz (CA, USA). Monoclonal mouse anti-β-Actin Cat# A5441 (AC-15) 
was purchased from Sigma-Aldrich (Munich, Germany). 
Rabbit anti-S100A4 was purchased from Sigma (MO, USA). Mouse monoclonal E-
selectin (CD62E) (BBIG-E4(5D11)) Cat# BBA16, was from R&D Systems (MN, 
USA). Mouse monoclonal antibody against Integrin β3 (CD61) (NCL-CD61-308) 
was purchased from Novocastra Laboratories Ltd. (Newcastle, UK). Mouse 
monoclonal anti-CD54 (ICAM-1) was purchased from Immunotech (Marseille, 
France). VE-cadherin (PN-IM1597) was purchased from Beckman Coulter (CA, 
USA). Mouse monoclonal CD44 (HCAM Ab-2 Clone 5F12) Cat# MS178-P0 was 
purchased from Thermo Scientific (MA, USA).  
PVDF-membrane was from GE-Healthcare (Amersham, Buckinghamshire, UK). 
Pierce-ECL Western Blotting Substrate Prod# 32106 was from Thermo Scientific 
(Portsmouth, USA). Hyperfilms ECL - High performance chemiluminescence film 
was from GE-Healthcare (Amersham, Buckinghamshire, UK). Polycolonal rabbit 
anti-mouse IgG and anti-rabbit were from Dako (Glostrup, Denmark). Lab-Tek II 
chambered coverglasses (*155382, size 4-well) were purchased from Nalge Nunc 
International (Wiesbaden, Germany). 
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Alexa-Fluor 488 (green) goat-anti-rabbit and Alexa-Fluor 594 (red) goat-anti-mouse 
labelled antibodies were purchased from Molecular Probes, Invitrogen (Karlsruhe, 
Germany). 
 
2.1.2 Cell culture 
Two different cell types were used. MCF-7 mock cells were grown in MEM medium 
(Gibco #61100-087, Invitrogen, Karlsruhe, Germany) supplemented with 10 % 
FCS, 1% Penicillin/Streptomycin, 1% NEAA (Gibco #11140-035 Invitrogen, 
Karlsruhe, Germany), 150 µg Hygromycin B (Roche #10843555 Vienna, Austria) at 
37°C in a humidified atmosphere containing 5% CO2. 
LECs (telomerase immortalized human lymphendothelial cells; T1S1) were grown 
in EGM 2 MV (Clonetics #CC-4147) at 37°C in a humidified atmosphere containing 
5% CO2.  
 
2.2. Methods 
2.2.1 Proliferation-Assay 
To determine the anti-proliferative effect of different chemicals MCF-7 cells were 
seeded at a concentration of 1 x 104 cells per ml into 24 well plates and grown for 
24 h to enter a logarithmic growth phase. Then they were incubated with increasing 
concentrations of the different chemicals (5, 25, 50, 75 µM) for 72 h. After 48 h and 
72 h the cells had to be washed with PBS, trypsinised and then they were counted 
with a Sysmex microcellcounter (Kobe, Japan). IC50 values for the chemicals were 
determined. All experiments were done in triplicate.  
 
Calculation to determine the percent of cell divisions compared to the untreated 
control: 
[(C72 h + drug – C48 h + drug) / (C72 h - drug – C48 h - drug)] x 100 = % cell division 
C72 h + drug ------ cell number after 72 h of drug treatment (5, 25, 50, 75 µM) 
C48 h + drug ------ cell number after 48 h of drug treatment (5, 25, 50, 75 µM) 
C72 h – drug ------ cell number after 72 h without drug treatment 
C48 h -- drug ------ cell number after 48 h without drug treatment 
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2.2.2 MCF-7 spheroid generation 
MCF-7 mock cells were transferred to 30 ml MEM medium with hygromycin B 
containing 20 % methylcellulose (6 ml). 150 µl of this cell suspension were 
transferred to each well of a 96 well plate (greiner bio-one, Cellstar 650185) to 
allow spheroid formation within the following two days. 
 
2.2.3 MCF-7 spheroid/LEC monolayer co-cultivation 
Method 1: 
LECs were seeded in 2 ml EGM 2 MV medium into 24 well plates (costar 3524) 
and allowed to grow for 2 days until confluence. Then, LECs were stained with 
cytotracker green (1:5000 dilution, Invitrogen, Molecular Probes #C2925) for 1 hour 
at 37°C. MCF-7 mock spheroids, which were treated with different concentrations 
(solvent, 5, 25, 50 and 75 µM) of chemicals for 30 min at 37°C, were carefully 
transferred to the wells of a 24 well plate containing LECs. These 3D MCF-7 
spheroids/LECs monolayer co-cultures were incubated for 4 h at 37°C. The size of 
the gaps, which were formed in the LEC monolayers were measured using a Zeiss 
Axiovert microscope. For each condition, the gap area under at least 12 spheroids 
was measured.  
 
Method 2: 
MCF-7 tumor spheroids were grown as described above (MCF-7 spheroid 
generation). LECs were seeded in 2 ml EGM 2 MV medium into 24 well plates and 
allowed to grow for 2 days until confluence. Then, LECs were stained with 
cytotracker green (1:5000 dilution) for 1 h at 37°C. Different settings of MCF-7 
spheroid/LEC inhibition or co-inhibition were used in one experiment. 
 As negative control MCF-7 spheroids were treated with DMSO for 30 min at 
37°C and then they were transferred to the 24 well plate containing LECs. 
 MCF-7 spheroid/LEC co-inhibition: MCF-7 spheroids were treated with 10 
µM Bay11-7082 for 30 min at 37°C and then they were also transferred. 
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 MCF-7 spheroid inhibition: MCF-7 spheroids were treated with 10 µM 
Bay11-7082 for 30 min at 37°C and afterwards washed with EGM 2 MV 
medium. Then, the spheroids were transferred to the 24 well plate. 
 LEC inhibition: LECs were treated with 10 µM Bay11-7082 for 30 min at 
37°C. In the next step LECs were washed with EGM 2 MV and untreated 
MCF-7 spheroids were transferred on the top of the cells. 
After the four transfer steps of treated, or in the fourth case, untreated MCF-7 
spheroids the MCF-7 spheroid/LEC co-cultures were incubated for 4 h at 37°C. 
Then, the size of the gaps, which were formed in the LEC monolayers were 
measured using a Zeiss Axiovert microscope. For each condition, the gap area 
under at least 12 spheroids was measured.  
 
Method 3: 
Lab-Tek II chambered coverslips (*155382, size 4 well) were coated with 10 µg/ml 
Fibronectin for 1 h at room temperature. MCF-7 spheroids were grown as describe 
above (MCF-7 spheroid generation). LECs were seeded in 1 ml EGM 2 MV on 
chambered coverslips and allowed to grow for 2 days. 
Different settings of MCF-7 spheroid/LEC inhibition or co-inhibition were used in 
one experiment. 
 As negative control MCF-7 spheroids were treated with DMSO for 30 min at 
37°C and then they were transferred to the 24 well plate containing LECs. 
 MCF-7 spheroid/LEC co-inhibition: MCF-7 spheroids were treated with 10 
µM Bay11-7082 for 30 min at 37°C and then they were also transferred. 
 MCF-7 spheroid inhibition: MCF-7 spheroids were treated with 10 µM 
Bay11-7082 for 30 min at 37°C and afterwards washed with EGM2MV 
medium. Then, the spheroids were transferred to the 24 well plate. 
 LEC inhibition: LECs were treated with 10 µM Bay11-7082 for 30 min at 
37°C. In the next step LECs were washed with EGM 2 MV and untreated 
MCF-7 spheroids were transferred on the top of the cells. 
After the incubation time of 4 h the cells were washed with ice cold PBS and fixed 
in 4 % paraformaldehyd for 15 min at room temperature. Cells were 
immunostained with various antibodies and analyzed with confocal microscope. 
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2.2.4 Immunofluorescence 
Cells were washed with ice cold PBS and fixed in 4 % paraformaldehyd for 10 min 
at room temperature. In the next step the cells were washed three times with PBS 
and permeabilised with 0.1 % Triton X-100 in 1X PBS for 30 min at room 
temperature. Then, cells were washed again three times with PBS and blocked for 
1 hour with 10 % goat serum diluted in BSA PBS. Thereafter, the cells were 
incubated with the primary antibody (dilution 1:50 – 1:400 depend on the antibody 
in 2 % BSA/PBS) for 1 hour at room temperature. After the incubation time of 1 
hour cells were washed again with PBS for three times. Then, cells were incubated 
with fluorescence labelled second antibody (dilution 1:1000 in 2% BSA/PBS) for 1 
hour at room temperature in the dark and washed with PBS. In the last step cells 
were counterstained for 4 min with the nuclear stain DAPI (dilution 1:50.0000) at 
room temperature and afterwards cells were covered with PBS and stored at 4°C 
for further analysis. 
 
2.2.5 Western Blotting 
MCF7 and LECs were seeded in 6 cm dishes. (Lysate1) MCF7 cells were treated 
with 10 µM Bay11-7082 for 30 min at 37°C. (Lysate2) LECs were treated with 1µM 
12SHETE for 0.2, 0.5, 2, 4 and 8 h. (Lysate3) LECs were pre-treated with 10 µM 
Bay11-7082 for 30 min and thereafter stimulated with 1 µM 12(S)-HETE for 0.2 and 
0.5 h at 37°C. 
Then, the cells were washed twice with ice cold PBS and lysed in buffer containing 
150 mM NaCl, 50 mM Tris pH 8.0, 0,1 % Triton-X100, 1 mM 
phenylmethylsulfonylfluorid (PMSF) and protease inhibitor cocktail (PIC). 
Afterwards the lysate was centrifuged at 12000 rpm for 20 min at 4°C and the 
supernatant was stored at -20°C until further analysis. 
Equal amounts of protein samples were separated by polyacrylamide gel 
electrophorese (PAGE) and electro-transferred onto Hybond PVDF-membranes 
(Amersham, Buckinghamshire, UK) at 100V for 1 h at 4°C. To control equal sample 
loading, membranes were stained with Ponceau S.  
After washing with PBS/T (Phosphate Buffered Saline/Tween 20; pH: 7.2) or 
TBS/T (Tris Buffered Saline/Tween 20; pH: 7.6) membranes were blocked in 
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blocking solution (5 % non-fat dry milk in TBS containing 0.1 % Tween or in PBS 
containing 0.5 % Tween 20) for 1 h at room temperature. 
Then membranes were washed carefully and incubated with the first antibody (in 
blocking solution; dilution 1:500 – 1:1000) by gently rocking at 4°C overnight or 1 h 
at room temperature. 
Thereafter, the membranes were washed another time with PBS/T or TBS/T and 
continuing incubated with the second antibody (peroxidase-conjugated goat anti-
rabbit IgG or anti-mouse IgG; dilution 1:2000) for 1 h at room temperature. 
Chemiluminescence was detected by ECL detection Kit and the membranes were 
exposed to Amersham Hyperfilms. 
 
2.2.6 Transient transfection with siRNA 
LECs were grown in 6 well plates to 70 % confluence in complete medium (EGM 2 
MV). Then, they were transfected using RNAiFectTM (Qiagen # 301607 Hamburg, 
Germany). 5 µg siRNA (siZEB1 RNA and scrambled RNA were from Prof. Andreas 
Eger) were diluted in culture medium, containing serum and antibiotics (final 
volume 100 µl). 15 µl of RNAiFect transfection reagent was added to the diluted 
siRNA and incubated for 15 min at room temperature. Then the mix was added to 
the cells and incubated for 8 h at 37°C. Thereafter the medium was changed and 
the cells were incubated further 48 h. 
 
2.2.7 Apoptose Assay – Hoechst 33258 and propidium iodide 
double staining 
To measure apoptosis in LECs, cells were grown in 96 well plates (200 µl 
medium/well) to 40 % confluence and then treated with 100 µM Baicalein, 1 µM 
12(S)-HETE and DMSO for 2, 4 and 24 h. Hoechst and propidium iodide (final 
concentrations 5 µg/ml and 2 µg/ml) were added to the culture medium for 1 h at 
37°C. Thereafter, stained cells were examined under a fluorescence microscope 
with DAPI filter, photographed, analyzed and counted manually. Experiments were 
done in triplicate. 
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2.2.8 Real-time PCR 
LECs were seeded in 12 well plates and then they were pre-treated with 10 µM 
Bay11-7082 for 30 min and thereafter stimulated with 1 µM 12(S)-HETE or with 
TNF-α (20ng/ml). Total RNA was isolated using the RNeasy Mini Kit 50 and 
QIAshredder 50 (Cat# 74104; Cat# 79654 QIAGEN, Hamburg, Germany). 1 µg of 
total RNA was reverse transcribed with Superscript First Strand Synthesis System 
(Cat.No. 11904-018; Invitrogen, Karlsruhe, Germany) and the resulting cDNA was 
amplified using TaqMan Universal PCR Master mix (No AmpErase UNG; PartNo 
4324018; Applied Biosystems Vienna, Austria) with the E-selectin Primer (TaqMan 
Gene Expression Assays Part No 4331182; Applied Biosystems Vienna, Austria). 
PCR products were analyzed on the Abi Prism 7000 sequence detection system 
(Applied Biosystems). Duplicate samples were analyzed in parallel. 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as internal control. 
Relative transcript expression was calculated using the ΔΔCT method. 
 
2.2.9 Statistical analysis 
Dose-response curves were analyzed using Prism 4 software (CA, USA) and 
significance was determined by student t-test. 
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3. Results 
Effect of Baicalein and the structurally highly related Wogonin on 
inhibition of gap formation 
Ductual breast cancer metastasis was shown to depend on the expression and 
activity of lipoxygenases in particular 12-LOX and to a minor extent 15-LOX, which 
generate 12(S)-HETE, a metabolite of arachidonic acid. 12(S)-HETE is produced 
and released by MCF-7 tumor cell spheroids and induces gaps in a LEC 
monolayer (Kerjaschki et al. 2010). A 3 dimensional (3D) co-culture system mimics 
the invading of breast cancer cells to the lymphatic vasculature and recapitulates 
the mechanism of metastasis (Kramer and Nicolson 1979, Uchide et al. 2007, 
Kerjaschki et al. 2010). Baicalein is reported to be a specific inhibitor of 12/15 
lipoxygenases and is a major constituent of the plant Scutellaria baicalensis (Chen 
et al. 1999, Hsieh et al. 2007) and Scutellaria orientalis (Özmen et al 2009). 
Another constituent of these plants is Wogonin which is structurally highly related 
to Baicalein (figure 1). Therefore, Wogonin was also tested in the gap formation 
assay and compared to Baicalein. The IC50 of Wogonin (75 µM) is lower than the 
IC50 value of Baicalein (100 µM). 
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Figure 1) Chemical structure of Baicalein (left) and Wogonin (right) and molecular weight. 
MW = 270,2 
 
MW = 284,3 
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Figure 2) Gap formation inhibition assay: LECs were seeded in 24 well plates and allowed to grow 
for 2 days until confluence. Then, LECs were stained with cytotracker green (1:5000 dilution) for 1 
hour at 37°C. MCF-7 mock cells were transferred to MEM medium with hygromycin B containing 
methylcellulose. 150 µl of this cell suspension were transferred to each well of a 96 well plate to 
allow spheroid formation within the following two days. Then, MCF-7 mock spheroids, which were 
treated with different concentrations (solvent, 5, 25, 50 and 75 µM) of  Wogonin and (solvent, 100 
µM) Baicalein for 30 min at 37°C, were carefully transferred to the wells of a 24 well plate containing 
LECs. These 3D MCF-7 spheroids/LECs monolayer co-cultures were incubated for 4 h at 37°C. The 
size of the gaps, which were formed in the LEC monolayers were measured using a Zeiss Axiovert 
microscope. For each condition, the gap area under at least 12 spheroids was measured. Error bars 
indicate SEM, asterisks significant gap formation inhibition compared to control (p<0.05). 
 
Induction of apoptosis in LECs by Baicalein 
To determine the apoptotic effects of 100 µM Baicalein and 1 µM 12(S)-HETE in 
LECs, cells were seeded in a 96 well plate and treated as mentioned in the chapter 
methods. In figure 3 we see that treatment of LECs with 100 µM Baicalein for 24 h 
induces apoptosis in approximately 80 % of the cells. In contrast to Baicalein 1 µM 
12(S)-HETE treated LECs showed no significant effect. 
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Figure 3) Apoptosis assay: cells were grown in 96 well plates (200 µl medium/well) to 40 % 
confluence and then treated with 100 µM Baicalein, 1 µM 12(S)-HETE and DMSO for 2, 4 and 24 h. 
Afterwards, cells were double stained with Hoechst and propidium iodide (final concentrations 5 
µg/ml and 2 µg/ml) for 1 h at 37°C. Thereafter, cells were examined under a fluorescence 
microscope with DAPI filter, photographed, analyzed and counted manually. Error bars indicate 
SEM, asterisks significant apoptosis induction compared to control (p<0.05). 
 
In preliminary experiments, besides 12(S)-HETE, we could identify also NF-ĸB as a 
major player in MCF7/LEC gap formation. Therefore, we tested compounds with 
putative NF-ĸB inhibitory properties in this 3D metastasis co-culture model. 
 34 
 
Di-galloyl-resveratrol inhibits lymphendothelial gap formation 
Earlier studies revealed that Di-galloyl-resveratrol (di-GA) (figure 4) was a strong 
inhibitor of gap formation and likely metastasis (Madlener et al. 2010). It was 
assumed that di-GA exerted the additive and synergistic effects of Resveratrol 
(RV) and Gallic acid (GA) (Madlener et al. 2010). Both are known to inhibit NF-ĸB.  
 
OH
O
O
O
OH
OH
OH
OH
OH
OH
O
 
Figure 4) Chemical structure of Di-galloyl-resveratrol (di-GA) and molecular weight 
 
Di-galloyl-resveratrol is a newly synthesized compound consisting of two GA 
molecules and one RV molecule (Bernhaus et al. 2009). 
It combines the biological effects of RV and GA, which both have anti-cancer 
activity in a number of tumor cell lines. Madlener et al. (2010) show the 
proapoptotic property of 10 µM di-GA and a 10 fold stronger growth inhibitory effect 
of di-GA as compared to GA.  
As mentioned above, di-GA is a strong inhibitor of gap formation. To investigate 
the contribution of the GA and RV moieties and derivatives in this assay, repetitive 
experiments were performed.  
Lymphendothelial cells (LECs) were grown (as described in the chapter methods) 
and MCF-7 tumor spheroids (containing 3000 cells) were transferred on top of 
confluent lymphendothelial cell-monolayers. LECs were stained with cytotracker 
green to show the presence or absence of LECs underneath tumor spheroids.  
 
MW = 532.47 
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MCF-7 spheroids were treated 30 min with increasing concentrations (5, 25, 50, 75 
µM) of the different compounds before co-cultivation. The gap size underneath the 
spheroid was measured 4 h after co-cultivation with a Zeiss Axiovert microscope. 
Di-GA (figure 5a) shows a dose-depended inhibition of gap formation with a 
maximum inhibition of about 70 %. 
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5b) 
 
Figure 5a) Gap formation inhibition assay: LECs were seeded in 2 ml EGM 2 MV medium on 24 
well plates and allowed to grow for 2 days until confluence. Then, LECs were stained with 
cytotracker green (1:5000 dilution) for 1 hour at 37°C. MCF-7 mock cells were transferred to 30 ml 
MEM medium with hygromycin B containing 20 % methylcellulose. 150 µl of this cell suspension 
were transferred to each well of a 96 well plate to allow spheroid formation within the following two 
days. Then, MCF-7 mock spheroids, which were treated with different concentrations of di-GA 
(solvent, 5, 25, 50 and 75 µM) for 30 min at 37°C, were carefully transferred to the wells of a 24 well 
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plate containing LECs. These 3D MCF-7 spheroids/LEC monolayer co-cultures were incubated for 
4 h at 37°C. The size of the gaps, which were formed in the LEC monolayers were measured using 
a Zeiss Axiovert microscope. For each condition, the gap area under at least 12 spheroids was 
measured. Error bars indicate SEM, asterisks significant gap formation inhibition compared to 
control (p<0.05). 5b) Upper panels are phase contrast micrographs showing the respective 
spheroids, the panels below show the identical power fields using FITC filter and exhibit green 
stained LECs underneath the respective spheroids. Scale bars: 100 µm. 
 
Efficiency of Resveratrol and its derivatives on cell proliferation and 
LEC gap formation 
Since RV (figure 6) is a part of the di-GA molecule, we compared the efficiency 
also of LEC gap formation. RV was found in grapes and red wine. It exhibits a 
remarkable inhibitory potential in various stages of tumor development. RV was 
shown to inhibit several molecular targets such as kinases and cyclooxygenases 
(Saiko et al. 2008). Several experiments have shown that RV suppresses the 
growth of cancer cells by inhibition of DNA polymerase (Locatelli 2005), 
ribonucleotide reductase (Fontecave et al. 1998), by inducing cell cycle arrest and 
apoptosis (Bourdon et al. 2007, Tanaka et al. 2000). 
To prove the proliferation inhibition MCF-7 cells were seeded at a concentration of 
1 x 104 cells per ml in 24 well plates and grown for 24 h. Then they were incubated 
with increasing concentrations (5, 25, 50, 75 µM) of RV and counted after 48 h and 
72 h. 49 µM RV inhibited 50 % MCF-7 proliferation between 48 – 72 h of incubation 
and 50 µM inhibited LEC gap formation by ~25 % (figure 7a, 7b).  
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Figure 6) Chemical structure of Resveratrol (RV) and molecular weight 
MW = 228,2 
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Figure 7a) Anti-proliferative effect of Resveratrol: MCF-7 cells were seeded (1 x 10
4
 cells/ml) in 24 
well plates and grown for 24 h. Then, they were incubated with increasing concentrations of 
Resveratrol (5, 25, 50, 75 µM) for 72 h. Cells were counted after 48 h and 72 h and the IC50 value 
for Resveratrol was determined. All experiments were done in triplicate. 7b) Gap formation inhibition 
assay: LECs were seeded in 24 well plates and allowed to grow for 2 days until confluence. Then, 
LECs were stained with cytotracker green (1:5000 dilution) for 1 hour at 37°C. MCF-7 mock cells 
were transferred to MEM medium with hygromycin B containing methylcellulose. 150 µl of this cell 
suspension were transferred to each well of a 96 well plate to allow spheroid formation within the 
following two days. Then, MCF-7 mock spheroids, which were treated with different concentrations 
(solvent, 5, 25, 50 and 75 µM) of Resveratrol for 30 min at 37°C, were carefully transferred to the 
wells of a 24 well plate containing LECs. These 3D MCF-7 spheroids/LEC monolayer co-cultures 
were incubated for 4 h at 37°C. The size of the gaps, which were formed in the LEC monolayers 
were measured using a Zeiss Axiovert microscope. For each condition the gap area under at least 
12 spheroids was measured. Error bars indicate SEM, asterisks significant gap formation inhibition 
compared to control (p<0.05). 
 
The bioavailability of Resveratrol is very low. An intravenous dose of RV is 
converted within approx. 30 min to sulfate conjugates in humans. Piceatannol 
(PIC) is a natural occurring Resveratrol metabolite. Cytochrome P450 catalyzes 
the hydroxylation of RV to Piceatannol (3,5,3’,4’-tetrahydroxy-trans-stilbene) (Saiko 
et al. 2008). PIC differs from RV by an additional hydroxyl group. Vo et al. (2009) 
describe the pro- and anti-carcinogenic mechanisms of Piceatannol. She shows 
that low PIC concentrations stimulated MCF-7 cell growth whereas very high PIC 
concentrations (150 µM) caused cell death. PIC exerts even more significant 
biochemical effects on tumor cells than RV itself. Therefore we tested PIC as an 
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inhibitor of gap formation. However, in the gap formation assay PIC showed no 
effect (data not shown). 
 
M5 (3,4’,5-trimethoxystilbene, figure 8) is the methoxylated stilbene derivative of 
RV. It exhibited a stronger activity than RV even in chemoresistant cancer cells 
(Bader et al. 2008). M5 inhibited the proliferation of MCF-7 mock cells more 
efficiently than RV (IC50: 7,5 and 9,2 µM, respectively) (Bader et al. 2008) but on 
the inhibition of gap formation M5 was less efficient than RV.  
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Figure 8) Chemical structure of M5 and molecular weight. 
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Figure 9) Gap formation inhibition assay: LECs were seeded in 24 well plates and allowed to grow 
for 2 days until confluence. Then, LECs were stained with cytotracker green (1:5000 dilution) for 1 
hour at 37°C. MCF-7 mock cells were transferred to MEM medium with hygromycin B containing 
methylcellulose. 150 µl of this cell suspension were transferred to each well of a 96 well plate to 
allow spheroid formation within the following two days. Then, MCF-7 mock spheroids, which were 
treated with different concentrations (solvent, 5, 25, 50 and 75 µM) of M5 for 30 min at 37°C, were 
carefully transferred to the wells of a 24 well plate containing LECs. These 3D MCF-7 
spheroids/LEC monolayer co-cultures were incubated for 4 h at 37°C. The size of the gaps, which 
were formed in the LEC monolayers were measured using a Zeiss Axiovert microscope. For each 
MW = 270,32 
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condition, the gap area under at least 12 spheroids was measured. Error bars indicate SEM, 
asterisks significant gap formation inhibition compared to control (p<0.05). 
  
M8 (3,3’,4,4’,5,5’-hexahydroxystilbene) was another RV analog that was tested 
(Figure 9). In human promyelocytic leukemia cells (HL-60) 72 h treatment with 6,25 
µM M8 inhibited 50 % cell growth (IC50) (Horvath et al. 2006).  
In our study 75 µM M8 inhibited 40 % of MCF-7 cell proliferation between 48-72 h 
of treatment and 30 % of gap formation in the 3D co-culture assay (figure 11a, 
11b). 
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Figure 10) Chemical structure of M8 and molecular weight. 
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Figur 11a) Anti-proliferative effect of M8: MCF-7 cells were seeded (1 x 10
4
 cells/ml) into 24 well 
plates, grown for 24 h to enter logarithmic growth phase. Then, they were incubated with increasing 
concentrations of M8 (5, 25, 50, 75 µM) for 72 h. Cells were counted after 48 h and 72 h and the 
IC50 value for M8 was determined. All experiments were done in triplicate. 11b) Gap formation 
inhibition assay: LECs were seeded into 24 well plates and allowed to grow for 2 days until 
confluence. Then, LECs were stained with cytotracker green (1:5000 dilution) for 1 hour at 37°C. 
MCF-7 mock cells were transferred to MEM medium with hygromycin B containing methylcellulose. 
 
MW = 276,25 
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150 µl of this cell suspension were transferred to each well of a 96 well plate to allow spheroid 
formation within the following two days. Then, MCF-7 mock spheroids, which were treated with 
different concentrations (solvent, 5, 25, 50 and 75 µM) of M8 for 30 min at 37°C, were carefully 
transferred to the wells of a 24 well plate containing LECs. These 3D MCF-7 spheroid/LEC 
monolayer co-cultures were incubated for 4 h at 37°C. The size of the gaps, which were formed in 
the LEC monolayers were measured using a Zeiss Axiovert microscope. For each condition, the 
gap area under at least 12 spheroids was measured. Error bars indicate SEM, asterisks significant 
gap formation inhibition compared to control (p<0.05). 
 
Influence of GA, Amidox, Didox and Trimidox on cell proliferation and 
gap formation 
Two gallic acid (GA; 3,4,5-trihydroxybenzoic acid) (figure 12) moieties that are 
attached to the RV-backbone constitute the di-GA molecule. GA is a 
polyhydroxyphenolic compound that can be found in various natural products like 
gallnuts, tea leaves, grapes, pineapples, bananas and red wine (Madlener et al. 
2007). 
GA together with RV might be responsible for the “French paradox”, a 40 % lower 
heart infarction incidence in the French population compared with other European 
countries (Renaud and De Lorgeril 1992). 
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Figure 12) Chemical structure of Gallic acid and molecular weight. 
 
GA is an excellent free radical scavenger and an inducer of differentiation and 
programmed cell death in a number of tumor cell lines (Salucci et al. 2002, Inoue et 
al. 1994, Isuzugawa et al. 2001, Sohi et al. 2003, Kawada et al. 2001). It may also 
play a role in the prevention of malignant transformation and cancer development. 
GA had a time and dose-depended anti-proliferative effect (figure 13a) on human 
breast cancer cells (IC50 75 µM), but on gap formation the free GA molecule 
showed no inhibitory effect. It even induced gap formation (figure 13b). 
MW = 170,1 
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Figure 13a) Anti-proliferative effect of GA: MCF-7 were seeded at a concentration of 1 x 10
4
 cells 
per ml in 24 well plates and grown for 24 h. Then, they were incubated with increasing 
concentrations of GA (5, 25, 50, 75 µM) for 72 h. Cells were counted after 48 h and 72 h and the 
IC50 value for GA was determined. All experiments were done in triplicate. 13b) Gap formation 
inhibition assay: LECs were seeded into 24 well plates and allowed to grow for 2 days until 
confluence. Then, LECs were stained with cytotracker green (1:5000 dilution) for 1 hour at 37°C. 
MCF-7 mock cells were transferred to MEM medium with hygromycin B containing methylcellulose. 
150 µl of this cell suspension were transferred to each well of a 96 well plate to allow spheroid 
formation within two days. Then, MCF-7 mock spheroids, which were treated with different 
concentrations (solvent, 5, 25, 50 and 75 µM) of GA for 30 min at 37°C, were carefully transferred 
to the wells of a 24 well plate containing LECs. These 3D MCF-7 spheroids/LEC monolyer co-
cultures were incubated for 4 h at 37°C. The size of the gaps, which were formed in the LEC 
monolayers were measured using a Zeiss Axiovert microscope. For each condition, the gap area 
under at least 12 spheroids was measured. Error bars indicate SEM, asterisks significant gap 
formation inhibition compared to control (p<0.05). 
 
Amidox (3,4-dihydroxybenzamidoxime) and Didox (3,4-
dihydroxybenzohydroxydroxamic acid) are two polyhydroxy-substituted 
benzohydroxamic acid derivatives which also act as free radical scavengers 
(Grusch et al. 2001).  
 
Their chemical structures are related to GA and like RV they inhibited 
ribonucleotide reductase (RR) (Madlener et al. 2007). RR is the rate-limiting 
enzyme for de novo DNA-synthesis. The activity of RR is significantly increased in 
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tumor cells and therefore RR is a target for anticancer-therapy (Grusch et al. 
2001). 
 
 
 
 
 
 
 
Figure 14) Chemical structure of Amidox (left) and Didox (right) and molecular weight. 
 
Amidox and Didox show a 50 % inhibition of proliferation when treated with a 
concentration of 75 µM (figure 15a, 16a). As GA, the two molecules have no 
inhibitory effect on the gap formation (figure 15b, 16b).  
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Figure 15a), 16a) Anti-proliferative effect of Amidox and Didox: MCF-7 cells were seeded (1 x 10
4
 
cells/ml) into 24 well plates, grown for 24 h to enter logarithmic growth phase. Then, they were 
incubated with increasing concentrations of Amidox or Didox (5, 25, 50, 75 µM) for 72 h. Cells were 
counted after 48 h and 72 h and the IC50 value for Amidox and Didox was determined. All 
experiments were done in triplicate. 15b), 16b) Gap formation inhibition assay: LECs were seeded 
into 24 well plates and allowed to grow for 2 days until confluence. Then, LECs were stained with 
cytotracker green (1:5000 dilution) for 1 hour at 37°C. MCF-7 mock cells were transferred to MEM 
medium with hygromycin B containing methylcellulose. 150 µl of this cell suspension were 
transferred to each well of a 96 well plate to allow spheroid formation within two days. Then, MCF-7 
mock spheroids, which were treated with different concentrations (solvent, 5, 25, 50 and 75 µM) of 
Amidox and Didox for 30 min at 37°C, were carefully transferred to the wells of a 24 well plate 
containing LECs. These 3D MCF-7 spheroids/LEC monolayer co-cultures were incubated for 4 h at 
37°C. The size of the gaps, which were formed in the LEC monolayer were measured using a Zeiss 
Axiovert microscope. For each condition, the gap area under at least 12 spheroids was measured. 
Error bars indicate SEM, asterisks significant gap formation inhibition compared to control (p<0.05). 
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Like RV, Amidox and Didox, Trimidox (3,4,5-trihydroxybenzamidoxime) is also an 
inhibitor of RR. Trimidox is a very effective and promising enzyme inhibitor and 
demonstrates excellent anticancer activity in animal tumor models (Fritzer-
Szekeres et al. 1998, Szekeres et al. 1994). 
 
 
 
 
 
 
Figur 17) Chemical structure of Trimidox and molecular weight. 
 
Treatment of MCF-7 cells with Trimidox caused a time- and dose-dependent 
decrease of cell-proliferation. However, the treatment of the MCF-7 spheroids with 
Trimidox induced gap formation in LEC monolayers significantly. 
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Figure 18a) Anti-proliferative effect of Trimidox: Proliferation assay: MCF-7 were seeded at a 
concentration of 1 x 10
4
 cells per ml in 24 well plates and grown for 24 h. Then, they were incubated 
with increasing concentrations of Trimidox (5, 25, 50, 75 µM) for 72 h. Cells were counted after 48 h 
and 72 h and the IC50 value for Trimidox was determined. All experiments were done in triplicate. 
18b) Gap formation inhibition assay: LECs were seeded into 24 well plates and allowed to grow for 
2 days until confluence. Then, LECs were stained with cytotracker green (1:5000 dilution) for 1 hour 
at 37°C. MCF-7 mock cells were transferred to MEM medium with hygromycin B containing 
methylcellulose. 150 µl were transferred to each well of a 96 well plate to allow spheroid formation 
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within two days. Then, MCF-7 mock spheroids, which were treated with different concentrations 
(solvent, 5, 25, 50 and 75 µM) of Trimidox for 30 min at 37°C, were carefully transferred to the wells 
of a 24 well plate containing LECs. These 3D MCF-7 spheroids/LEC monolayer co-cultures were 
incubated for 4 h at 37°C. The size of the gaps, which were formed in the LEC monolayer were 
measured using a Zeiss Axiovert microscope. For each condition, the gap area under at least 12 
spheroids was measured. Error bars indicate SEM, asterisks significant gap formation inhibition 
compared to control (p<0.05). 
 
In summary all of the compounds which were tested caused a time- and dose-
dependent inhibition of MCF-7 cell proliferation. As mentioned above di-GA shows 
a dose-depended inhibition of gap formation with a maximum inhibition of about 70 
%. Therefore, we anticipated that all constituents of di-GA may exhibit inhibitory 
effects on gap formation but the free molecule GA showed no inhibitory effect. It 
even induced the gap formation as well as the polyhydroxy-substituted 
benzohydroxamic acid derivatives Amidox, Didox and Trimidox. RV and its analog 
M5 and M8 showed an inhibition of gap formation but not as efficient as di-GA. The 
strong inhibitory effect on gap formation of di-GA is apparently not due to the GA 
residues and only in part to RV. Therefore, di-GA has a novel anti-metastatic 
property of it own. 
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Effect of natural compounds on gap formation  
Among the synthetic drugs we also studied other natural compounds to test the 
inhibition of gap formation. Hyperforin, a main constituent of Hypericum perforatum 
and Hypericum adenotrichum is such a natural compound (Özmen et al. 2009). 
Hyperforin was shown to inhibit tumor growth, induce apoptosis of tumor cells and 
reduce tumor vascularisation (Schempp et al. 2005). It inhibited tumor invasion and 
metastasis as well (Dell Aica et al. 2007).  
 
  
Figure 19) Picture of Hypericum perforatum and  
chemical structure of Hyperforin and molecular weight. 
 
Treatment of MCF-7 spheroids with 75 µM Hyperforin caused a significant 30 % 
inhibition of gap formation (figure 20), which is consistent with its known NF-ĸB 
inhibitory property (Lorusso et al. 2009). 
 
 
 
 
 
 
 
MW = 536,79 
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Figure 20) Gap formation inhibition assay: LECs were seeded into 24 well plates and allowed to 
grow for 2 days until confluence. Then, LECs were stained with cytotracker green (1:5000 dilution) 
for 1 hour at 37°C. MCF-7 mock cells were transferred to MEM medium with hygromycin B 
containing methylcellulose. 150 µl of this cell suspension were transferred to each well of a 96 well 
plate to allow spheroid formation within two days. Then, MCF-7 mock spheroids, which were treated 
with different concentrations (solvent, 5, 25, 50 and 75 µM) of Hyperforin for 30 min at 37°C, were 
carefully transferred to the wells of a 24 well plate containing LECs. These 3D MCF-7 
spheroids/LEC monolayer co-cultures were incubated for 4 h at 37°C. The size of the gaps, which 
were formed in the LEC monolayer were measured using a Zeiss Axiovert microscope. For each 
condition, the gap area under at least 12 spheroids was measured. Error bars indicate SEM, 
asterisks significant gap formation inhibition compared to control (p<0.05). 
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Inhibition of NF-ĸB with the well accepted irreversible and specific 
inhibitor Bay11-7082 
 
As shown by other groups (Pierce et al. 1997; Zhu et al. 2008) Bay11-7082 (E)-3-
[(4-methylphenylsulfonyl]-2-propenenitrile (figure 21) inhibits the phosphorylation of 
cytokine-induced I-ĸBα and NF-ĸB translocation into the nucleus and therefore also 
its activity.  
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Figure 21) Chemical structure of Bay11-7082 and molecular weight. 
 
Therefore, NF-ĸB inhibition through stabilization of I-ĸBα, blocks the expression of 
ICAM-1, VCAM-1 and E-selectin in TNF-α treated HUVECS (Pierce et al. 1997). 
 
Exposure of the 3D cell culture model, with increasing concentration of Bay11-
7082 caused a complete inhibition of gap formation already at 15 µM.  
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Figure 22) Gap formation inhibition assay: LECs were seeded into 24 well plates and allowed to 
grow for 2 days until confluence. Then, LECs were stained with cytotracker green (1:5000 dilution) 
for 1 hour at 37°C. MCF-7 mock cells were transferred to MEM medium with hygromycin B 
MW = 207,3 
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containing methylcellulose. 150 µl of this cell suspension were transferred to each well of a 96 well 
plate to allow spheroid formation within two days. Then, MCF-7 mock spheroids, which were treated 
with different concentrations (solvent, 5, 25, 50 and 75 µM) of Bay11-7082 for 30 min at 37°C, were 
carefully transferred to the wells of a 24 well plate containing LECs. These 3D MCF-7 
spheroids/LEC monolayer co-cultures were incubated for 4 h at 37°C. The size of the gaps, which 
were formed in the LEC monolayer were measured using a Zeiss Axiovert microscope. For each 
condition, the gap area under at least 12 spheroids was measured. Error bars indicate SEM, 
asterisks significant gap formation inhibition compared to control (p<0.05). 
 
This tempted us to investigate whether this effect was due to the inhibition of NF-
ĸB in the MCF-7 cell spheroid or in the LEC-layer. The fact that Bay11-7082 is an 
irreversible inhibitor and the specific design of the following experiments allowed to 
discriminate which of the cell type-specific NF-ĸB activity contributed to the gap 
forming effect. 
 
Spheroids, which were treated with 10 µM Bay11-7082 for 30 min caused a gap 
formation of ~40 – 50 %. A similar level of inhibition was seen when the drug was 
washed off the MCF-7 spheroid to prevent LEC inhibition from contaminating Bay 
remnants (figure 22 third bar). Treatment of MCF-7 spheroids with increasing 
concentrations of Bay11-7082 (>10 µM) prevented a stable attachment of the 
spheroids to LEC-monolayers and gap formation. This let us assume that Bay11-
7082 inhibited a mechanism that was necessary for the adhesion of MCF-7 cells to 
LECs. The Bay11-7082 treatment of LECs and subsequent washoff showed that 
gap formation of LECs was inhibited by ~ 60 % and LECs lost their cell-cell 
contacts. The loss of LEC cell-cell contacts underneath the MCF-7 spheroids and 
the lack of centrifugal migration gave rise to a curly cloudy pattern of LEC 
distribution. 
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Figure 23) Gap formation inhibition assay: LECs were seeded into 24 well plates and allowed to 
grow for 2 days until confluence. Then, LECs were stained with cytotracker green (1:5000 dilution) 
for 1 hour at 37°C. MCF-7 mock cells were transferred to MEM medium with hygromycin B 
containing methylcellulose. 150 µl of this cell suspension were transferred to each well of a 96 well 
plate to allow spheroid formation within two days. Then, MCF-7 mock spheroids, which were treated 
in different ways (see chapter methods) were carefully transferred to the wells of a 24 well plate 
containing LECs. These 3D MCF-7 spheroids/LEC monolayer co-cultures were incubated for 4 h at 
37°C. The size of the gaps, which were formed in the LEC monolayer were measured using a Zeiss 
Axiovert microscope. 23a) Bar chart which shows the inhibition of gap formation. For each 
condition, the gap area under at least 12 spheroids was measured. Error bars indicate SEM, 
asterisks significant gap formation inhibition compared to control (p<0.05). 
23b) Pictures exhibit green stained LECs (using FITC filter) underneath the respective spheroids. 
The red mark shows the outline of the spheroid.  
 
As described above treatment of LECs with Bay11-7082 results in a cloudy cell 
distribution (figure 23b below right panel). This cell distribution pattern suggested 
that LECs lost their cell-cell contact underneath the spheroid, but did not migrate 
thereby opening a gap. To study this effect in more detail we used 
immunofluorescence combined with confocal laser scanning microscopy. 
 
NF-ĸB regulates LEC motility through ZEB1 dependent VE-cadherin 
expression 
 
Cadherins are cell adhesion molecules which mediate adhesion via homophilic 
Ca2+-dependent interactions. They can be devided into epithelial cadherin (E-
cadherin), neural cadherin (N-cadherin), placental cadherin (P-cadherin), muscle 
cadherin (M-cadherin) and vascular endothelial cadherin (VE-cadherin). 
VE-cadherin is expressed specifically in endothelial cells. Vascular endothelial 
(VE)-cadherins are calcium-dependent adhesive proteins which are of vital 
importance for the maintenance and control of endothelial cell contacts. Cadherins 
bind directly to β-catenin (cytoplasmic protein) required for optimal adhesive 
function (Vestweber 2008). VE-cadherin is required for intact cell-cell interaction 
and is a marker for an epithelial and immotile cell phenotype.  
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It was shown that 12(S)-HETE induces endothelial cell retraction (Honn et al. 1994) 
and stimulates tumor cell spreading on matrix (Timar et al. 1992). 12(S)-HETE was 
produced and released from MCF-7 cells (Uchide et al. 2007). Therefore, tumor 
cell-induced endothelial cell retraction is a major step in breast cancer metastasis 
(Kerjaschki et al. 2010).  
To simplify the MCF-7 spheroids/LEC co-culture system and facilitate Western blot 
analysis we treated LECs with 1 µM 12(S)-HETE and found a transient 
downregulation of VE-cadherin expression (figure 24a, 24b).  
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Figure 24) Analysis of VE-cadherin expression. 24a) LECs were treated with 1 µM 12(S)-HETE for 
0.2, 0.5, 2, 4 and 8 h. Then, cells were harvested and protein lysates were analysed by western 
blotting. MCF-7 cells were used as negative control. Equal sample loading was controlled by β-actin 
analysis. 24b) Densitometry of VE-cadherin expression normalised by β-actin expression. 
 
Figure 25 shows the 12(S)-HETE triggered VE-cadherin downregulation using the 
MCF-7 spheroid/LEC co-culture system by immunofluorescence. MCF-7 spheroids 
and LECs were grown as mentioned above and after an incubation time of 4 h cells 
were fixed with 4 % paraformaldeyhd and immunostained with the antibody against 
VE-cadherin (red). Figure 25a shows that in some distance to a spheroid VE-
cadherin cell-cell interactions were well developed, whereas underneath a MCF-7 
spheroid VE-cadherin interactions were apparently disrupted (figure 25b).  
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25a)     25b) 
 
Figure 25) Confocal images of LECs a) next to a spheroid and b) under a MCF-7 spheroid. LECs 
were seeded on chambered coverslips and allowed to grow for 2 days until confluence. MCF-7 
spheroids were treated with DMSO for 30 min at 37°C and transferred on top of LECs. MCF-7 
spheroids/LECs were incubated for 4 h at 37°C to allow gap formation. Then cells were fixed for 15 
min in ice cold 4 % paraformaldehyd and stained with VE-cadherin following incubation with Alexa 
Fluor 594-conjugated anti mouse (red) IgG and DAPI (blue). 
 
In epithelial tumors activation of the embryonic program epithelial-mesenchymal 
transition is important for the dissemination and invasion of cancer cells (Yilmaz et 
al. 2007). Loss of epithelial differentiation and development of a mesenchymal 
phenotype allows separation of cancer cells from the primary tumor mass and 
spreading into the surrounding stroma. Loss of E-cadherin is a key initiating event 
in epithelial-mesenchymal transition (EMT) (Thiery 2002). It enables the first step 
of metastasis – local invasion and dissemination of cancer cells from the main 
tumor mass. 
ZEB1 is a transcriptional repressor and known to downregulate the E-cadherin 
expression (Schmalhofer et al. 2009). High ZEB1 expression correlated with loss of 
E-cadherin expression and increased migratory and invasive potential (Arumugam 
et al. 2009). As mentioned above we found a 12(S)-HETE induced downregulation 
of VE-cadherin expression in LECs. Therefore we also tested the correlation of 
ZEB1 and VE-cadherin expression and the influence of Bay11-7082 on LEC 
motility. 
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ZEB1 was found primarily in the nucleus as a transcriptional factor and inducer of 
EMT (Arumugam et al. 2009). Figure 26 shows that treatment of LECs with 1 µM 
12(S)-HETE for 10 min increased the ZEB1 expression and decreased the VE-
cadherin expression. Pre-treatment with 10 µM Bay11-7082, an inhibitor of NF-ĸB, 
for 30 min caused a decrease of ZEB1 expression and induction of VE-cadherin 
expression. Therefore, NF-ĸB activation is associated with induction of ZEB1 
expression. (Chua et al. 2007) Taken together, our results show an inverse 
relationship between ZEB1 and VE-cadherin. A decrease of ZEB1 and an increase 
of VE-cadherin expression caused by Bay11-7082 resulted in loss of MCF-7 
invasiveness and LEC-migration. 
 
26) 
 
 
 
 
Figure 26) Analysis of ZEB1 and VE-cadherin protein 
expression. LECs were pre-treated with 10 µM Bay11-
7082 for 30 min and stimulated with 1 µM 12(S)-HETE for 
10 min. Then, cells were harvested and protein lysates 
were analysed by western blotting. MCF-7 cells were used 
as negative control. Equal sample loading was controlled 
by β-actin analysis.  
 
 
 
 
 
 
Figure 27 shows the analysis of ZEB1 and VE-cadherin expression by 
immunofluorescence using a laser scanning confocal microscop. MCF-7 spheroids 
and LECs were grown as mentioned above and after incubation time of 4 h the 
system were fixed with 4 % paraformaldeyhd and immunostained with the antibody 
against ZEB1 (green) and VE-cadherin (red). Upper panels (figure 27a) show the 
high ZEB1 expression of LECs underneath a MCF-7 spheroid correlated with loss 
of VE-cadherin expression and consequently an increased migratory phenotype of 
lymphendothelial cells, which is a prerequisite for cancer cells to invade the 
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vasculature. The panels below (figure 27b) show the inhibition of ZEB1 expression 
by Bay11-7082 and as a result the increased VE-cadherin expression.  
 
27a) 
 
 
 
 
 
 
 
27b) 
 
Figure 27) Confocal images of LECs under MCF-7 spheroids. LECs were seeded on chambered 
coverslips and allowed to grow for 2 days until confluence. MCF-7 spheroids were treated with a) 
DMSO or with b) 10 µM Bay11-7082 for 30 min at 37°C and transferred on top of LECs. MCF-7 
spheroids/LECs were incubated for 4 h at 37°C to allow gap formation. Then cells were fixed for 15 
min in ice cold 4 % paraformaldehyd and stained with ZEB1 and VE-cadherin following incubation 
with Alexa Fluor 488-conjugated anti-rabbit (green) and Alexa Fluor 594-conjugated anti mouse 
(red) IgGs and DAPI (blue). 
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The Western blot data (figure 26) suggested that ZEB1 seemed to negatively 
regulate VE-cadherin expression. To test this we transiently transfected LECs with 
siRNA to specifically knock down the expression of ZEB1. This resulted in a loss of 
VE-cadherin regulation upon 12(S)-HETE stimulation (figure 28a, 28b). 
 
28a) 
 
28b) 
                   ZEB1 expression
sc
ra
m
bl
e 
-1
2(
S)
-H
ET
E
sc
ra
m
bl
e 
+1
2(
S)
-H
ET
E
si
ZE
B
-1
 R
N
A
 -1
2(
S)
-H
ET
E
si
ZE
B
-1
 R
N
A
 +
12
(S
)-H
ET
E
si
ZE
B
-1
' R
N
A
 -1
2(
S)
-H
ET
E
si
ZE
B
-1
' R
N
A
 +
12
(S
)-H
ET
E
0
25
50
75
100
%
 o
f 
E
xp
re
ss
io
n
                   VE-Cadherin expression
sc
ra
m
bl
e 
-1
2(
S)
-H
ET
E
sc
ra
m
bl
e 
+1
2(
S)
-H
ET
E
si
ZE
B
-1
 R
N
A
 -1
2(
S)
-H
ET
E
si
ZE
B
-1
 R
N
A
 +
12
(S
)-H
ET
E
si
ZE
B
-1
' R
N
A
 -1
2(
S)
-H
ET
E
si
ZE
B
-1
' R
N
A
 +
12
(S
)-H
ET
E
0
25
50
75
100
%
 o
f 
E
xp
re
ss
io
n
 
Figure 28) Analysis of ZEB1 and VE-cadherin protein expression. LECs were transiently transfected 
with siZEB1 RNA and scrambled RNA. Then, LECs were treated with 1 µM 12(S)-HETE. Afterwards 
cells were harvested and protein lysates were analysed by western blotting using antibodies against 
ZEB1 and VE-cadherin. Equal sample loading was controlled by β-actin analysis 28a) western blot 
analyses of ZEB1 and VE-cadherin expression 28b) Densitometer readings of ZEB1 and VE-
cadherin western blots. 
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Another independent marker of motility (EMT) S100A4 
To substantiate the migratory phenotype of LECs underneath the spheroids, the 
3D cultures were analysed with S100A4 antibody in absence and presence of 
Bay11-7082 because S100A4 is a marker for cell motility and EMT.  
S100A4 is a calcium-binding protein that interacts with intracellular target proteins 
(Mandinova et al. 1998). S100A4 is able to induce metastasis in rodent models for 
breast cancer. S100A4 has been associated with migratory and invasive properties 
(Rudland et al. 2000). mRNA for S100A4 has been shown to be at a higher level in 
breast carcinoma than in benign breast tumor specimens (Wang et al. 2000). 
S100A4 overexpression leads to an increase of invasiveness and motility of the 
cancer cells. Beside that, S100A4 acts as an angiogenic factor by stimulating the 
motility and invasiveness of endothelial cells (Takenaga et al. 1994, Jenkinson et 
al. 2004, Ambartsumian et al. 2001, Schmidt-Hansen et al. 2004). 
As mentioned earlier, ductal breast cancer metastasis was shown to depend on the 
expression and activity of lipoxygenases in particular 12-LOX, which generate 
12(S)-HETE (Kerjaschki et al. 2010). To determine whether 12(S)-HETE may 
affect the S100A4 expression in dependence of NF-ĸB, we examined the levels of 
S100A4 in LECs. Therefore, LECs were pre-treated with 10 µM Bay11-7082 and 
then stimulated for 30 min with 1 µM 12(S)-HETE. Figure 29 shows that S100A4 
expression was activated by treatment of LECs with 1 µM 12(S)-HETE, whereas 
the pre-treatment of LECs with Bay11-7082 caused an inactivation of S100A4 
expression which implicates the involvement of NF-ĸB in S100A4 regulation.  
 
29) 
 
Figure 29) Western blot analysis of S100A4 expression. LECs 
were treated with 1µM 12(S)-HETE for 30 min and 10µM 
Bay11-7082 for 30 min. Then, cells were harvested and the 
expression of S100A4 were analysed by western blotting using 
an antibody against S100A4. β-actin was used as a loading 
control. 
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Figure 30 (confocal image upper panel) shows the induction of S100A4 under the 
spheroids and therefore, the higher motility of endothelial cells. The treatment of 
spheroids with Bay11-7082 inhibited the expression of S100A4. 
 
30a) 
     
30b) 
     
Figure 30) Confocal images of LECs under MCF-7 spheroids. LECs were seeded on chambered 
coverslips and allowed to grow for 2 days until confluence. MCF-7 spheroids were treated with a) 
DMSO or with b) 10 µM Bay11-7082 for 30 min at 37°C and transferred on top of LECs. MCF-7 
spheroids/LECs were incubated for 4 h at 37°C to allow gap formation. Then cells were fixed for 15 
min in ice cold 4 % paraformaldehyd and stained with S100A4 and VE-cadherin following incubation 
with Alexa Fluor 488-conjugated anti-rabbit (green) and Alexa Fluor 594-conjugated anti mouse 
(red) IgGs and DAPI (blue). 
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Evidence for inter-specific cell-cell adhesion 
The adhesion of tumor cells to the endothelial cells represents the first important 
event in the process of metastasis (Honn et al. 1987). Therefore, we examined the 
possible role of bonafide NF-kB-regulated ligand – receptor pairs in tumor cell 
adhesion to the endothelium.  
 
ICAM-1 and αLβ2 integrin 
Intracellular adhesion molecule 1 (ICAM-1) is a member of the immunoglobulin 
gene superfamily and an inducible counter receptor for several leukocyte β2 
integrins. Endothelial cells constitutively express ICAM-1 (Collins et al. 1995). 
Bolick and colleagues (2005) have shown that 12(S)-HETE stimulates NF-ĸB 
activation and NF-ĸB dependent ICAM-1 expression through RhoA and PKCα. We 
chose to use 1 µM 12(S)-HETE as the concentration for our studies. We added 
1µM 12(S)-HETE for 0.2, 0.5, 2, 4, and 8 h at 37°C to LEC monolayers and found a 
small induction of ICAM-1 expression (figure 31a). After pre-treatment of LECs with 
10 µM Bay11-7082 for 30 min and stimulation with 12(S)-HETE for 10 min ICAM-1 
induction was inhibited (figure 31b). The best-known ligands for ICAM-1 are the β2 
integrins (Rosenstein et al. 1991). In our study we could not detect β2 integrin in 
MCF-7 cells by western blot analysis, although MCF-7 cells were described to 
express this integrin subtype and LFA-1 (Budinsky et al. 1997). 
MUC1 (also known as tumor-associated epithelia mucin, polymorphic epithelial 
mucin or epithelial membrane antigen) is a 69- amino-acid long cytoplasmic 
domain and is well suited to support intercellular adhesion (Parry et al. 1990). It 
was shown that tumor cell-associated MUC1 can mediate endothelial adhesion 
through ICAM-1 and this suggested that also MUC1 may play a crucial role in 
promoting tumor cell survival and metastasis (Regimbald et al. 1996). 
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31a)    31b) 
 
Figure 31) Analysis of ICAM-1 expression. a) LECs were treated with 1 µM 12(S)-HETE for 0.2, 0.5, 
2, 4 and 8 h b) LECs were pre-treated with 10 µM Bay11-7082 for 30 min and stimulated with 1 µM 
12(S)-HETE for 10 min. Then, cells were harvested and protein lysates were analysed by western 
blotting using an antibody against ICAM-1. MCF-7 cells were used as control. Equal sample loading 
was controlled by β-actin analysis.  
 
When NF-ĸB is inhibited by Bay11-7082 it leads to a loss of contact and therefore 
to a reduction in LEC motility and gap formation.  
 
CD31 and αVβ3 integrin 
Integrins are receptors for cell-surface adhesion molecules and extracellular matrix 
(ECM) proteins. Integrin αVβ3 is also known as vitronectin receptor and consists of 
an α and a β subunit (Rupp and Little 2001). 
The vitronectin receptor has been implicated in the pathophysiology and 
progression of malignant tumors such as breast cancer (Harms et al. 2004, Vellon 
et al. 2006). A positive correlation of the increased expression of αVβ3 integrin with 
the ability of the cancer cells to adhere to extracellular matrix and to migrate was 
shown in in vitro studies (Rolli et al. 2003, Felding-Habermann et al. 2001).  
αVβ3 integrin characterizes the metastatic phenotype in breast cancer. It is up-
regulated in invasive tumors and distant metastasis (Liapis et al. 1996). 
Deryungina et al. (2000) have shown the high expression of the αV subunit and the 
lower expression of the β3 subunit in MCF-7 cells.  
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CD31 (platelet-endothelial cell adhesion molecule 1; PECAM1) is found to be a 
ligand for αVβ3 integrin (Piali et al. 1995). CD31 is a member of the immunoglobulin 
superfamily. It is a pivotal constituent of the endothelial cell intercellular junction 
and because of this cellular expression pattern CD31 is implicated in several 
functions, including transendothelial migration of leukocytes, angiogenesis and 
integrin activation (Newman 1999). 
 
Figure 32a) shows a time-dependent induction of CD31 expression with a 
maximum after 8 h of treatment with 1 µM 12(S)-HETE. As anticipated, MCF-7 
cells showed no CD31 expression. The pre-treatment of LECs with 10 µM Bay11-
7082 for 30 min and stimulation with 12(S)-HETE for 30 min caused an inhibition of 
CD31 expression in LECs (figure 32b). 
 
32a)    32b) 
 
Figure 32) Analysis of CD31 expression. a) LECs were treated with 1 µM 12(S)-HETE for 0.2, 0.5, 
2, 4 and 8 h b) LECs were pre-treated with 10 µM Bay11-7082 for 30 min and stimulated with 1 µM 
12(S)-HETE for 30 min. Then, cells were harvested and protein lysates were analysed by western 
blotting using an antibody against CD31. MCF-7 cells were used as control. Equal sample loading 
was controlled by β-actin analysis.  
 
We did not detect a regulation of αVβ3 integrin by Bay11-7082 in MCF-7 cells 
although integrin αVβ3 was described to be regulated by NF-ĸB (Scatena et al. 
1998) 
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E-selectin and CD44 
CD44 is a cell surface glycoprotein and acts as a adhesion molecule in cell-
substrate and cell-cell interactions, in lymphocyte recruitment to inflammatory sites 
and tumor metastasis (Khan et al. 2004, Wang et al. 2005, Naor et al. 1997, 
Spessotto et al. 2002). 
Endothelial leukocyte adhesion molecule-1 (E-selectin) plays a pivotal role in 
mediating cell-cell interactions between tumor cells and endothelial monolayer 
during tumor metastasis. (Laferriere et al. 2002) Several studies have 
demonstrated a critical role for E-selectin in regulating tumor cell transendothelial 
migration in breast cancer cells. (Tozeren et al. 1995, Moss et al. 2000) 
Zen et al. (2008) demonstrated that the CD44 variant 4 serves as a major E-
selectin ligand in mediating breast cancer cell transendothelial metastasis. We 
could demonstrate that CD44 is highly upregulated in MCF-7 spheroids compared 
to MCF-7 monolayers (Kerjaschki et al. 2010). 
 
Figure 33 shows the expression of E-selectin in LECs by real-time quantitative 
PCR. Stimulation of LECs with 20ng/ml TNF-α for 60 min at 37°C show a strong 
induction of E-selectin expression whereas the stimulation of LECs with 1 µM 
12(S)-HETE show no effect. Pre-treatment of TNF-α stimulated LECs with 10 µM 
Bay11-7082 show an inhibition of the E-selectin expression. 
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Figure 33) Analysis of E-selectin expression by real-time quantitative PCR: a) LECs were grown in 
12 well plates and pre-treated with 10 µM Bay11-7082 for 30 min and thereafter stimulated with 
20ng/ml TNF-α for 60 min at 37°C. b) LECs were grown in 12 well plates and pre-treated with 10 
µM Bay11-7082 for 30 min and thereafter stimulated with 1 µM 12(S)-HETE for 30 min and 60 min 
at 37°C. PCR products were analyzed on the Abi Prism 7000 sequence detection system. Duplicate 
samples were analyzed in parallel. GAPDH served as internal control. Relative expression numbers 
calculated using the ΔΔCT method. 
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4. Discussion 
The metastatic process was found to include many steps such as dissociation of 
tumor cells from the bulk tumor, invasion of tumor cells, intravasation, transport 
through vessels, extravasation and outgrowth of secondary tumors (Geiger and 
Pepper 2009). Kramer and Nicolson (1979) have described the interaction of 
tumorigenic cells with vascular endothelial cells a long time ago. Here, we used a 
3D co-culture system to mimic the invading of breast cancer cells to the lymphatic 
vasculature and recapitulated the mechanism of metastasis. Metastasis was 
shown to depend on the expression and activity of lipoxygenases (Uchide et al. 
2007, Kerjaschki et al. 2010). 
Lipoxygenases are enzymes which metabolize arachidonic acid to biologically 
active eicosanoids. Several studies have shown their involvement in tumor 
differentiation and progression (Jiang et al. 2006, Nithipatikom et al. 2006, Chen et 
al. 2005).  
Targeted inhibition of LOX isoforms can inhibit the proliferation of a variety of tumor 
cells (Tong et al. 2002, Ma et al. 2005). Since, Baicalein was found to be a 12-LOX 
inhibitor (Chen et al. 1999) and in breast cancer increased levels of 12-LOX were 
identified (Jiang et al. 2006), we assumed that Baicalein have an inhibitory effect 
on the gap formation. Wang et al. (2010) described the strong anti-proliferative 
effect of Wogonin and Baicalein, major constituents of the plant Scutellaria 
baicalensis, on MCF-7 cells. Wogonin is structurally highly related to Baicalein. We 
demonstrated that Baicalein inhibits the invasivity of MCF-7 cells indicated by 
reduced lymphendothelial gap formation. Hence, we also expect that Wogonin 
might have an inhibitory effect on gap formation.  
Yet, Wogonin has not been described to be a 12/15-LOX inhibitor. However, 
Wogonin inhibited gap formation more efficiently than Baicalein and therefore 
Wogonin seems to be a more potent 12/15-LOX inhibitor than Baicalein. 
 
To confirm that the gap formation was not due to apoptosis of LECs, we performed 
apoptosis assay and found that treatment with 1 µM 12(S)-HETE had no effect and 
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treatment with 100 µM Baicalein did not induce apoptosis within the time settings of 
the gap formation assay. 
 
It was reported that in cancer NF-ĸB activation is associated with tumor cell 
proliferation, survival, invasion and angiogenesis (Brown et al. 2008). This makes 
NF-ĸB an interesting target for the treatment of cancer.  
 
Bay11-7082 is an agent that has been reported to irreversibly inhibit NF-ĸB 
triggered gene expression (Pierce et al. 1997). 
 
In this study we found that treatment of MCF-7 spheroids with increasing 
concentration of Bay11-7082 caused a complete inhibition of gap formation. These 
data suggested that NF-ĸB is involved in the process of gap formation. We 
designed specific experiments that allowed us to discriminate whether this effect 
was due to the inhibition of NF-ĸB in the MCF-7 spheroid or in the LEC-layer. 
Concentrations of Bay11-7082 higher than 10 µM prevented the attachment of the 
spheroids to LEC-monolayers. This demonstrated that Bay11-7082 inhibited a 
mechanism that was necessary for the adhesion of MCF-7 cells to LECs. Another 
important aspect of Bay11-7082 – mediated NF-ĸB inhibition of LECs was the 
cloudy LEC distribution which suggested that LECs lost their cell-cell contact 
among themselves underneath the spheroid, but did not migrate and therefore 
failed to open a gap. 
This observation rendered us to investigate the role of VE-cadherin, because 
cadherins are known to facilitate stable lateral cell-cell links via homophilic Ca2+-
dependent interactions. Different types of cadherins were described. VE-cadherin 
is reported to be specifically expressed in endothelial cells and it is a marker for an 
epithelial and immotile cell phenotype (Vestweber 2008). 
To simplify the MCF-7 spheroid/LEC co-culture system we treated LEC with 1 µM 
12(S)-HETE, because we could demonstate that this molecule is the gap forming 
factor of MCF-7 cells (Kerjaschki et al. 2010). 
Here we found by western blot analysis and immunofluorescence that VE-cadherin 
is expressed in LECs (which to our best knowledge, was not described before) and 
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treatment of LECs with 12(S)-HETE caused a transient downregulation of VE-
cadherin expression.  
This was consistent with the fact that LECs lost their cell-cell contacts underneath 
spheroid because VE-cadherin interactions were indeed disrupted, and that VE-
cadherin is associated with an immobile phenotype. 
Furthermore we observed a 12(S)-HETE triggered increase of ZEB1 expression in 
LECs. ZEB1 is a transcriptional repressor and known to downregulate E-cadherin 
expression (Schmalhofer et al. 2009). Loss of E-cadherin is reported to be a key 
initiating event in epithelial-mesenchymal transition, the first step of metastasis 
(Thiery 2002). High ZEB1 expression was described to be associated with an 
increased migratory and invasive potential (Arumugam et al. 2009). Since it was 
not known that ZEB1 also downregulates VE-cadherin we investigated in a siRNA 
approach whether knockdown of ZEB1 would cause loss of VE-cadherin regulation 
by 12(S)-HETE, which was in fact the case. Further we observed a Bay11-7082 
induced decrease of ZEB1 by western blot analysis and immunofluorescence. This 
implicated the involvement of NF-ĸB in the regulation of ZEB1, VE-cadherin and 
LEC motility. Also Chua et al. (2007) found that NF-ĸB activation is associated with 
induction of ZEB1 expression. 
 
Another independent marker of motility is S100A4. Rudland et al. (2000) showed 
that S100A4 has been associated with migratory and invasive properties. 
Extracellular addition of S100A4 activates NF-ĸB through induction of 
phosphorylation and subsequent degradation of I-ĸBα (Boye et al. 2008). We found 
that 12(S)-HETE induced S100A4 and Bay11-7082 inhibited S100A4 expression 
which directly correlated with LEC motility. These results propose that 12(S)-HETE 
induces EMT in LECs although this interpretation is somewhat problematic, 
because LECs are of mesenchymal origin yet with an epitheloid phenotype. 
 
The adhesion of tumor cells to the endothelial cells represents the first important 
event in the process of metastasis (Honn et al. 1987). In our study we described 
the possible role of three bonafide NF-ĸB-regulated ligand – receptor pairs in tumor 
cell adhesion to the endothelium. Intracellular adhesion molecule 1 is a member of 
the immunoglobulin gene superfamily and the best-known ligands for ICAM-1 are 
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the β2 integrins (Collins et al. 1995, Rosenstein et al. 1991). ICAM-1 is 
constitutively express in endothelial cells whereas the β2 integrins were described 
to be express by MCF-7 cells (Collins et al. 1995, Budinsky et al. 1997). The 
contact of these two molecules allows MCF-7 cells to attach to the endothelial 
monolayer. 
Bolick et al. (2005) demonstrated that 12(S)-HETE stimulates NF-ĸB activation and 
NF-ĸB dependent ICAM-1 expression through RhoA and PKCα. We found that pre-
treatment of LECs with 10 µM Bay11-7082 for 30 min and stimulation with 12(S)-
HETE for 10 min inhibited the ICAM-1 expression. This data suggest that MCF-7 
spheroids can not attach to the LECs after treatment with Bay11-7082. In our study 
we could not detect β2 integrin in MCF-7 cells by western blot analysis probably 
due to antibody failure.  
 
Another NF-ĸB-regulated ligand – receptor pair, which is important for the adhesion 
of tumor cells to the endothelium, is CD31 and αVβ3 integrin. CD31 is a pivotal 
constituent of the endothelial cell intercellular junction and was described to be a 
ligand for αVβ3 integrin (Piali et al. 1995). αVβ3 integrin also known as vitronectin 
receptor has been implicated in the progression of malignant tumors such as 
breast cancer (Harms et al. 2004, Vellon et al. 2006). It was described to be 
regulated by NF-ĸB (Scatena et al. 1998). 12(S)-HETE treatment of LECs showed 
a time-dependent induction of CD31 expression and pre-treatment of LECs with 
Bay11-7082 caused its inhibition. 
 
CD44 was described to be a major E-selectin ligand in mediating breast cancer cell 
transendothelial metastasis (Zen et al. 2008). CD44 was highly upregulated in 
MCF-7 spheroids compared to MCF-7 monolayers (Kerjaschki et al. 2010). To 
demonstrate the expression of E-selectin in LECs we performed real-time 
quantitative PCR. Here, we only found a TNF-α triggered stimulation of E-selectin 
expression and further a Bay11-7082 inhibition. Treatment of LECs with 12(S)-
HETE showed no effect on the E-selectin expression. Never the less, constitutive 
expression of E-selectin could have been sufficient to facilitate E-selectin – CD44 
mediated LEC- MCF-7 spheroid adhesion. 
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Besides 12(S)-HETE we could identify NF-ĸB as a major player in MCF-7 
spheroid/LEC gap formation through specific inhibitor Bay11-7082 experiments. 
Bay11-7082 is not used in clinical therapies. Therefore, we tested the newly 
synthesized compound di-GA that combines the biological effects of RV and GA, 
which both were described to have anti-cancer activity in a number of tumor cell 
lines and to have health beneficial effects (RV). Madlener et al. (2010) described 
the strong inhibitory activity of di-GA in gap formation. We also tested the 
derivatives of RV and GA assuming that also these compounds as free molecules 
exhibited inhibitory effects on gap formation. All of the tested compounds showed 
strong anti-proliferative effects on MCF-7 cells which is a hallmark for anti-tumor 
activity. Di-GA is a compound which consist of two GA molecules and one RV 
molecule (Bernhaus et al. 2009). 
RV was found in grapes and red wine whereas GA can be found also in grapes, 
red wine gallnuts, tea leaves, pineapples, bananas (Madlener et al. 2007, Saiko et 
al. 2008). RV modulates several biochemical processes involved in carcinogenesis 
(Saiko et al. 2008, Kundu and Surh 2004). It was reported to inhibit angiogenesis 
and metastasis, inflammation and tumor progression and the carcinogen activation 
and DNA-adduct formation (Dubuisson et al. 2002, Ciolino and Yeh 1999, Banerjee 
et al. 2002, Kimura and Okuda 2001). 
The di-GA constituent RV and its analogous M5 and M8 showed an inhibition of 
gap formation by 20 – 30 % but that was not as efficient as di-GA. 
Indeed GA and its polyhydroxy-substituted benzohydroxamic acid derivatives 
showed no inhibitory effects on gap formation. They even induce it. 
 
Treatment of cancer involves several conventional modalities such as surgical 
resection, radiation therapy and chemotherapy. 60 % of all effective anticancer 
drugs used in western medicine are derived from natural compounds however 
there are still a lot of unexplored resources in herbal medicines which needs to be 
tested (Cragg et al. 2006, Balunas and Kighorn 2005).  
Among the synthetic drugs we also observed the effect of natural compounds on 
gap formation. A main constituent of Hypericum perforatum and Hypericum 
adenotrichum is Hyperforin (Özmen et al. 2009).  
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Hyperforin was described to inhibit tumor growth, induce apoptosis of tumor cells 
and reduce tumor vascularisation (Schlempp et al. 2005). Dell Aica et al. (2007) 
reported that it inhibited tumor invasion and metastasis as well. 
In the present study we found a significant 30 % inhibition of gap formation, which 
is may be due to its NF-ĸB inhibitory property. 
The RV and hyperforin doses used in this study are certainly too high for in vivo 
studies and therefore, these natural components are unlikely to be successful in an 
adjuvant therapy. However, these compounds could act in synergy with standard 
therapies and may play a role in tumor prevention. 
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